 
    
Protocol Title : A Phase 2, Multicenter, International, 
Single Arm Study To Assess The Safety  And Efficacy Of 
Single Agent CC -486 (Oral Azacitidine) In Previously 
Treated Subjects With Locally Advanced Or Metastatic 
Nasopharyngeal Carcinoma  
 
NCT Number:  NCT 02269943  
Original Protocol  Date:  11 July 2014  

',6&/2685(
5('$&7('25,*,1$/[ZIP_CODE]&2/
&&13&
$3+$6(08/7,&(17(5,17(51$7,21$/6,1*/($50678'<72$66( 66
7+(6$)(7<$1'()),&$&<2)6,1*/($*(17&&25$/$=$&,7,',1 (
,135(9,286/<75($7('68%-(&76:,7+/2&$//<$'9$1&('25
0(7$67$7,&1$623+$5<1*($/&$5&,120$
7KHLQIRUPDWLRQFRQWDLQHGLQWKHDWWDFKHGUHSRUWLVWKHSURSHUW \RI&HOJHQHDQGVKRXOGQRWEHVKDUHGRU
XVHGIRUDQ\SXUSRVHRWKHUWKDQWKDWIRUZKLFKLWZDVSURYLGHG 

&HOJHQHLVFRPPLWWHGWRSURYLGLQJLQIRUPDWLRQDERXWLWVFOLQLFDOWULDOVWRUHVHDUFKHUVDQGSDWLHQWVZLWKWKHJRDORIIXUWKHULQJVFLHQFHDQGHQKDQFLQJKHDOWKFDUHZRUOGZLGH/DZVDQGUHJXODWLRQVUHTXLUHKRZHYHUWKDW&HOJHQHSURWHFWVSDWLHQWSULYDF\7KHFRPSDQ\PD\IXUWKHU KDYHOHJDORUFRQWUDFWXDOREOLJDWLRQVQRW
WRGLVFORVHFRPPHUFLDORUWHFKQLFDOLQIRUPDWLRQSURYLGHGE\RU UHODWHGWRFHUWDLQSDUWQHUFRPSDQLHVRU
YHQGRUV7KHDWWDFKHGUHSRUWLVSUHVHQWHGLQLWVRULJLQDOIRUPDWEXWFH UWDLQLQIRUPDWLRQKDVEHHQUHGDFWHGLQRUGHU
WRFRPSO\ZLWKWKHDIRUHPHQWLRQHGREOLJDWLRQVRUWRSURWHFW&HO JHQHÂ¶VFRQILGHQWLDOFRPPHUFLDO
LQIRUPDWLRQ7KHUHGDFWLRQVDUHEDVHGRQWKHIROORZLQJSULQFLSOHV

x5HGDFWHGLQIRUPDWLRQKDVEHHQUHSODFHGE\JUH\VSDFHPDLQWDLQL QJRULJLQDOVSDFLQJDQGSDJLQDWLRQ
x$Q\LQIRUPDWLRQWKDWPLJKWDOORZWKHLGHQWLILFDWLRQRILQGLYLGX DOVKDVEHHQUHGDFWHGIRU
DQRQ\PL]DWLRQ
x$WWDFKPHQWVWRWKLVUHSRUWWKDWFRQWDLQFRQILGHQWLDOLQIRUPDWLR QDUHQRWPDGHDYDLODEOH6XFK
DWWDFKPHQWVLQFOXGHWKRVHWKDWFRQWDLQLGHQWLILDEOHSDWLHQWLQIRUPDWLRQVXFKDVVXEMHFWOLVWLQJV
QDUUDWLYHVDQGSURILOHV7KH\DOVRPD\FRQWDLQFRQILGHQWLDOFRPPHUFLDOLQIRUPDWLRQVXFKDVPHWKRGRORJLHVDQGK\SRWKHVLVJHQHUDWLQJDQGH[SORUDWRU\DQDO\V HV
x&URVVUHIHUHQFHVWRWKHVHDWWDFKPHQWVVXFKDVOLQNVWRVXEMHFW OLVWLQJVLQ6HFWLRQDUHQRW
UHGDFWHGIURPWKHERG\RIWKHUHSRUW+RZHYHUWKHK\SHUOLQNV LQWKHHOHFWURQLFGRFXPHQWDUHQR
ORQJHUIXQFWLRQDO
x,QIRUPDWLRQDERXW&HOJHQHYHQGRUVDQGWKHLUVHUYLFHVDUHUHGDFW HGEHFDXVHPDQ\FRQWUDFWVSURKLELW
GLVFORVXUHRIWKDWLQIRUPDWLRQ)XUWKHUODZVDQGUHJXODWLRQV SUHYHQWXVIURPGLVFORVLQJFHUWDLQ
LQIRUPDWLRQDERXWRXUYHQGRUVRUWKHLUVHUYLFHVEHFDXVHLWLVS URWHFWHGE\FRS\ULJKW

,QIRUPDWLRQDERXW&HOJHQHÂ¶VUHGDFWLRQSROLFLHVDQGWKHDYDLODEL OLW\RIDGGLWLRQDOGDWDIURPWKLVUHSRUWPD\
EHIRXQGDWKWWSZZZFHOJHQHFRPUHVHDUFKGHYHORSPHQWFOLQLFDOWULDOVFOLQLFDOWULDOVGDWDVKDULQJ

&(/*(1([ZIP_CODE],ILIL5,(7$5<,1)250$7,2166
1(1(
55
RWEHVKDUHGRWEHVKDUHG
FKHUVDQGSDKHUVDQ
JXOJXODWLRQVUHDWLRQVU
DORUFRUFRQWUDFRQWUDF
WRFHUWDLQSDFHUWDLQS
DLQLQIRUPDWLQLQIRUPDW
&HOJHQHÂ¶VF&HOJHQHÂ¶V
SULQFLSOHVSULQFLSOHV
H\VSDFHPDVSDFHPD
FDWLRQRILFDWLRQRIL
QFRQILGHQFRQILGWLDWL
DLQLGHQWLILDLQLGHQWLI
OVRPD\FRQOVRPD\FRQ
LVJHQHUDWLQVJHQHUDWL
DWWDFKPHQWVWWDFKPHQ
RIWKHUHSRRIWKHUH
W&HOJHQHY&HOJHQHY
KDWLQIRUPDWKDWLQIRUPD
DERXWRXUYDERXWRXU
RQDERXW&HDERXW&H
QGDWKWWSZQGDWKWWSZ
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 1 CC-486-NPC-001 Final: 11 July 2014TITLE PAGE
A PHASE 2, MULTICENTER, INTERNATIONAL, 
SINGLE ARM STUDY TO ASSESS THE SAFETY AND 
EFFICACY OF SINGLE AGENT CC-486 (ORAL 
AZACITIDINE) IN PREVIOUSLY TREATED SUBJECTS 
WITH LOCALLY ADVANCED OR METASTATIC 
NASOPHARYNGEAL CARCINOMA
INVESTIGATIONAL PRODUCT (IP): CC-486 (Oral Azacitidine)
PROTOCOL NUMBER: CC-486-NPC-001
DATE FINAL: [ADDRESS_78647] NUMBER: 2014-001745-25
IND NUMBER: 122556
SPONSOR NAME / ADDRESS: Celgene Corporation
[ADDRESS_78648]
Summit, NJ 07901[LOCATION_002]
CONFIDENTIAL
This protocol is provided to you as an Investigator, potential Investigator, or consultant for review by 
[CONTACT_10825], your staff, and ethics committee/institutional review board.  The information contained in this 
document is regarded as confidential and, except to the extent necessary to obtain informed consent, 
may not be disclosed to another party unless such disclosure is required by [CONTACT_27614].  
Persons to whom the information is disclosed must be informed that the information is confidential 
and may not be further disclosed by [CONTACT_476].ided to you asided to yo
and ethics coand ethics co
regarded as cgarded as c
not be disclosenot be disclos
ons to whom ns to whom5235,(7$5<,1)250$7,21S S 
citcitidine)idine
001001
144
4-001745--001745
122556122556
Celelgeg
8686
5252
/*/*
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 2 CC-486-NPC-001 Final: 11 July 2014MEDICAL MONITOR / EMERGENCY CONTACT [CONTACT_72620]:
Name :
[CONTACT_1641]:  
Address: Route de Perreux 1,
Boudry, Switzerland  2017
Phone:
E-mail :
Note: The back-up [ADDRESS_78649] call center should only be used if you 
are not able to reach the Clinical Research Physician(s) or Medical Monitor or designee for 
emergency calls
Back-up [ADDRESS_78650] Call Center: 
&(/*(1([ZIP_CODE],(7$5<,1)250$7,2105000
25)2
er should or should
Medical MMedic
enter: enter: $57$$5
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 3 CC-486-NPC-001 Final: 11 July 2014CELGENE THERAPEUTIC AREA HEAD SIGNATURE [CONTACT_1783]
{See appended electronic signature [CONTACT_3264]}
Signature [CONTACT_72655] [CONTACT_27616], I indicate I have reviewed this protocol and find its content to be 
acceptable.  ,1,1)250$7,210$0$5000
s content toconten
,1
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 4 CC-486-NPC-001 Final: 11 July 2014SITE PRINCIPAL INVESTIGATOR [INVESTIGATOR_27503]:_______________________________________
By [CONTACT_27616], I agree to personally supervise the conduct of this study at my study 
site and to ensure its conduct is in compliance with the protocol, informed consent, Institutional Review Board (IRB)/Ethics Committee (EC) procedures, instructions from 
Celgene representatives, the Declaratio n of Helsinki, ICH Good Clinical Practices 
Guidelines, and local regulations governing the conduct of clinical studies.
&(/*(1([ZIP_CODE],(7$5$5$5<,1)250$7,210$0$[ADDRESS_78651] of clinicaof clinic
$5
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 5 CC-486-NPC-001 Final: 11 July 2014COORDINATING PRINCIPAL INVESTIGATOR [INVESTIGATOR_27504]:_______________________________________
By [CONTACT_27616], I agree the protocol has been written to comply with ICH Good 
Clinical Practices guidelines and agree to offer guidance throughout the study as needed.
&(/*(1([ZIP_CODE],(7$5<5<5<,1)wiwi1)250$7,210$0$[ADDRESS_78652]
5<
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 6 CC-486-NPC-001 Final: 11 July 2014PROTOCOL SUMMARY
Study Title
A Phase 2, Multicenter, International, Single Arm Study to Assess the Safety and Efficacy of 
Single Agent CC-486 (Oral Azacitidine) in Previous ly Treated Subjects With Locally Advanced 
or Metastatic Nasopharyngeal Carcinoma
Indication
Subjects with locally advanced or metastatic nasopharyngeal carcinoma (NPC) with an 
undifferentiated or poorly differentiated carcinoma, who have previously progressed clinically or radiographically on 1 to 2 previous regimens including platinum-based chemotherapy.
Objectives
Primary Objectives:
To evaluate the efficacy of CC-486 in subjects with NPC
Secondary Objectives:
To evaluate safety in all subjects and pharmacokinetics (PK) of CC-486 in a subset of subjects of 
Asian-Pacific Island ethnicity at experienced selected sites
Exploratory Objective:
 
Study Design
This is a Phase 2, single arm, multicenter, international study to assess the safety and efficacy of 
single agent CC-486 in previously tr eated subjects with locally advanced or metastatic NPC, 
having previously failed one to two previous  regimens, including a platinum-based 
chemotherapy.
Approximately 51 to 55 subjects will be enro lled acc ording to a Simon two-stage design; if the 
predefined activity is met (> 4 responses [com plete response/partial response {CR/PR}] out of 
the first 17 evaluable subjects based on independent  radiological assessment), then the study will 
continue to enroll an additional 34 subjects. If â‰¤ [ADDRESS_78653] imated median 
survival for the entire enrolled population of approximately 8 to 10 months.&(/*(1([ZIP_CODE],(r, internatr, interna io
ated ated subjecsub
previous previous 
bjects will bjects will
t (t (>[ADDRESS_78654]
ulationulation
dydywillwilly  be c be ll
lylydifferentdifferenyy
wo o priprior oregreg7$5<,1)250$7,21inically or inically o
pypy..
CCCC--486 in4
Length Length(7$,(7
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 7 CC-486-NPC-001 Final: 11 July 2014All subjects will be followed for safety and monit oring of adverse events (AEs) for [ADDRESS_78655] (IP), for response until progression (if applicable), and for 
new anticancer therapi[INVESTIGATOR_72591], or the End of 
Trial, whichever occurs earlier.
The End of Trial is defined as either the date of the last visit of the last subject to complete the 
study, or the date of receipt of the last data point from the last subject that is required for 
primary, secondary, and/or exploratory analysis, as prespecified in the protocol and/or the Statistical Analysis Plan, whichever is the later date.
Study Treatments
Subjects will receive the investigational produ ct (IP) CC-486, administered orally every day 
(QD) on Days 1-[ADDRESS_78656] 6 evaluable for 
safety subjects of Asian-Pacific Island ethnicity, a starting dose of 200 mg will be tested. If there 
are no safety concerns, eg, unexpected AEs or serious adverse events (SAEs), AEs leading to discontinuation, or death, the [ADDRESS_78657] refusal, physician decision, or 
death.
Overview of Efficacy Assessments
All subjects will be evaluated for tumor response and progression according to Response 
Evaluation Criteria In Solid Tumors (RECIST) v1.1 guidelines at screening and every 6 weeks 
(Â± 5 days) for the first three tumor evaluation s and then every 9 weeks until documented disease 
progression, start of new anticancer therapy, or withdrawal of consent.
Response assessmen ts will in clude computed tom ography (CT) scan or magnetic resonance 
imaging (MRI) of the head and neck with supraclavicular node imaging, the chest and
abdomen/pelvis, neurological examination with facial nerve evaluation, and bone scans at 
baseline for all subjects. Bone scans will be repeated  only if the subject is symptomatic or with 
known bone metastasis .
In the follow-up phase, anticancer treatment administered following the last dose of IP and survival will be followed every 8 weeks (Â± 5 days ) until death, withdrawal of consent, or lost-to-
follow up, whichever occurs first.
Overview of Safety Assessments
All subjects will be monitored for adverse events, starting from the time the subject signs the 
Informed Consent Form (ICF) until [ADDRESS_78658] dose of IP. A thorough evaluation of 
medical conditions will be conducted during screening for eligibility. Documented physical 
examination, vital signs, laboratory assessments , (eg, serum chemistry, hematology, including 
Epstein-Barr virus [EBV] â€“ deoxyribonucleic acid [DNA]), and Eastern Cooperative Oncology 
Group (ECOG) performance status will be monitored regularly ( Oken, 1982 ) see Appendix A.
Preventative measure will be taken to avoid pregna ncy in study subjects or their partners, and 
females of child-bearing potential will have regular pregnancy testing performed. The full schedule of assessments is described in Table 1 and Section 6.&(/*(1([ZIP_CODE],(7$5<,1)250$7,21ry dayy day
valuable valuable fof
e tested. If e tested. If
AEs lAEs l eadineadi
equent subjquent subj
on, unaccepn, unacce
refusal, phyfusal, ph
progressioprogressio
1 gui1 gu delinedeline
and then evnd then e
or wior wi ththiiidrawdraw
puted uted ttomomog
witwith suprach sup
minatnaion win w
cans will bcans will b
ntnticancernce t
wed everywed every 8y
er occurs foccurs f
Safety Asseafety As
ts will be mwill be m
d Consent d Consent
cal conditcal condit i
aminataminat ioionn
EpsteinEpstein -BB
Group roup
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 8 CC-486-NPC-001 Final: 11 July 2014Overview of Statistical Methods
This Phase 2 multicenter, single-arm study is designed to evaluate the overall response rate 
(ORR) and progression-free survival (PFS) of CC-486 in previous ly treated subjects  with locally 
advanced or metastatic nasopharyngeal carcinoma, having received one to two previous 
regimens. A Simonâ€™s optimal two-stage design will be used ( Simon, 1989).
Analysis Population
All safety analyses will be based on th e population of all enro lled s ubjects who received at least 
one dose of IP. All primary and secondary efficacy analyses will be based on the Efficacy 
Evaluable population, wh ich consists of all subjects who meet all eligibility criteria, and
EITHER received at least two cycles of IP at any dose intensity and discontinued treatment for 
progressive disease; OR received at least four cycles of IP at any dose intensity and have 
baseline and at least two post-screening tumor assessments.
Sample Size
The sample size est imation is based on having s ufficient sample in the Efficacy Evaluable 
population to show that the ORR is higher than 20% or median PFS is > 5 months. Simonâ€™s 
optimal two-stage design will be used. In the first stage, 17 subjects will be accrued. If there are 4 or fewer responders within these 17 subjects, enrollment will be stopped. Otherwise 34 
additional subjects will be accrued for a total of 51 subjects. This Phase 2 study will be 
considered positive if more than 14 responders are observed in 51 subjects or the hypothesis of median PFS equal to 5 months is rejected. This design yields a marginal one-sided type I error 
rate of 5% and power of 85% when the true ORR is 40%. After the second stage (n = 51), the power for showing median PFS is > 5 months is 80% (60%) when the true median PFS is about 8 (7) months.
Efficacy Analysis
Efficacy analyses will be performed on the efficacy evaluable population.
The hypothesis testing for the ORR will be based on the exact binomial distribution. Point 
estimate and two-sided 90% confidence interval (CI) of ORR will be provided. The hypothesis 
testing for the PFS will be based on the exponential distribution. Median PFS, OS, and their two-sided 90% CIs will be provided.
Safety Analysis
Safety and tolerability will be monitored through continuous reporting of AEs and serious 
adverse events (SAEs), laboratory abnormalities , and incidence of subjects experiencing dose 
modifications, dose interruptions, and/or premature discontinuation of IP. Data from all subjects who receive one or more doses of IP w ill be included in the safety analyses. Adverse events, 
physical examinations (including vital sign measurements), clinical laboratory information, and 
concomitant medications/procedures will be tabulated.
All adverse events will be summarized by [CONTACT_35043], severity grade based on the National 
Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) (Version 4.0) 
and relationship to treatment. Adverse events will be coded according to the Medical Dictionary 
for Regulatory Activities (MedDRA) and will be su mmarized by [CONTACT_5379] 
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21ment for ment for 
have have 
fficacy Evaficacy f
s > 5 months > 5 month
ts will be acs will be a
be stoppedbe stopped
This This Phhaseas
ed in 51 sued in 51 su
yields a mayields a m
40%. Afte40%. Aft
80%80% (60%)(60%
on the on the efficaef
RR will be bR will be
onfidence innfidence i
based on theased on t
oviovded.ed.
bilitbility willy will l
s(SAEs)(SAEs) l
ons, dose inns, dose in
eive one oreive one o
ical examinical exami
ncomitant ncomitant 
All Alladvedv
nc
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 9 CC-486-NPC-001 Final: [ADDRESS_78659], and events leading to discontinuation 
or death will be listed separately.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 10 CC-486-NPC-001 Final: 11 July 2014TABLE OF CONTENTS
TITLE PAGE ..............................................................................................................................1
PROTOCOL SUMMARY ..........................................................................................................6
1. INTRODUCTION..................................................................................................16
1.1. Nasopharyngeal Carcinoma ....................................................................................16
1.2. Diagnosis and Treatment ........................................................................................17
1.3. CC-486 ...................................................................................................................18
1.3.1. CC-486 Experience in Solid Tum ors.......................................................................19
1.3.2. CC-486 in Nasopharyngeal Carcinoma (NPC) ........................................................[ADDRESS_78660] Version 1.1 ...................................33
[IP_ADDRESS]. Other Assessments ..................................................................................................34&(/*(1([ZIP_CODE],(7$5<,1)250$7,2177
.......1818
..................... 191
.........................
..........................
.........................
..........................
...........................
......................
.................
........................
.....................
...........................
....................
......................
...........................
.......................
EVENTSVENT
URESURES ......
ment Perment Per ioi
nd of Treand of Trea
FoFollolloww
.. EffEffif
.2.2..2.2
.3..3.
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 11 CC-486-NPC-001 Final: [ADDRESS_78661](s) ................................................................[ADDRESS_78662] Disposition .................................................................................................45
10.6. Efficacy Analysis ....................................................................................................45
10.7. Safety Analy sis.......................................................................................................45
10.8. Interim Analy sis .....................................................................................................46
10.9. Assessment of Pharmacokinetics ............................................................................46
10.10. Other Topi [INVESTIGATOR_1102]...........................................................................................................46&(/*(1([ZIP_CODE],(7$5<,1)250$7,2166
.......373
..............393
.........................
..........................
..........................
..........................
....................
..................
..................... ....
......................
yand Dispoand Dispo
ce......................
IONS ANDONS AND
edications ications 
nt MediM catc
itant Meditant Medi
L ANALYANALY
........................
yyPopulPopulyy aatitionon
ammple Siple Simmm zeze
BackgroBackgro
SubjSu
[IP_ADDRESS].
[IP_ADDRESS].
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 12 CC-486-NPC-001 Final: 11 July 201411. ADVERSE EVENTS..............................................................................................47
11.1. Monitoring, Recording and Re porting of Advers e Even ts .......................................47
11.2. Evaluation of Adve rse Events.................................................................................47
11.2.1. Se riousness............................................................................................................. 47
11.2.2. Severity / Int ensity..................................................................................................49
11.2.3. Causality ................................................................................................................49
11.2.4. Durati on .................................................................................................................50
11.2.5. Action Tak en..........................................................................................................50
11.2.6. Outcom e................................................................................................................. 50
11.3. Abnormal Laboratory Values..................................................................................50
11.4. Pregnanc y...............................................................................................................50
11.4.1. Females of Childbear ing Potential: .........................................................................[ADDRESS_78663]/Independent Ethics Committee Review and 
Approval ................................................................................................................[ADDRESS_78664] / Ethics Committee ................58
14.8. Closure of th e Study ...............................................................................................58
15. DATA HANDLING AND RECORDKEEPI[INVESTIGATOR_1645] .....................................................59&(/*(1([ZIP_CODE],(7$5<,1)250$7,[ADDRESS_78665] Info
ConfideConfide
ProtPro
[IP_ADDRESS].
7
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 13 CC-486-NPC-001 Final: 11 July 201415.1. Data/Documen ts .....................................................................................................[ADDRESS_78666] Reten tion....................................................................................................59
16. QUALITY CONTROL AND QUALITY ASSURANCE ........................................61
16.1. Study Monitoring and S ource Data Veri ficatio n......................................................61
16.2. Audits and Ins pections............................................................................................61
17. PUBLICATIONS ...................................................................................................62
18. REFERENCES.......................................................................................................63
19. APPENDICES ........................................................................................................66
Appendix A. Eastern Cooperative Oncology  Group (ECOG) Performance Status...................66
&(/*(1([ZIP_CODE],(7$5<,1)250$7,2111
.......626
..............636
.........................
tusus.................
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 14 CC-486-NPC-001 Final: [ADDRESS_78667] OF TABLES
Table 1: Table of Events.......................................................................................................26
Table 2: Schedule of Pharmacokinetic Blood Sample Collection in the 
Pharmacokinetics Phase..........................................................................................34
Table 4: Dose Adjustments and Dose Delays for Toxicity ....................................................40
Table 5: Eastern Cooperative Oncology G roup (ECOG) Performance Statu s........................66
&(/*(1([ZIP_CODE],(7$5<,1)250$7,2100
......66
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 15 CC-486-NPC-001 Final: [ADDRESS_78668] OF FIGURES
Figure 1: Study Design ..........................................................................................................25
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 16 CC-486-NPC-001 Final: [ADDRESS_78669] 
common cancer originating in the nasopharynx, which is composed of the upper part of the 
throat (pharynx) behind the nose. The pharynx is composed of three sections: the hypopharynx, 
the oropharynx, and the nasopharynx.
The nasopharynx lies just above the soft palate of the mouth and just in the back of the nasal 
passages, serving as a passageway for air from the nose to the throat and eventually to the lungs. 
Anatomically, it has a cuboidal shape that extends from the base of the skull to the upper surface of the soft palate. The lateral walls are formed by [CONTACT_72621] (a deep recess, aka the pharyngeal recess). Anteriorly, the nasopharynx abuts the 
posterior choana and nasal cavity, and the pos terior boundary is formed by [CONTACT_72622]. 
Above the pharyngeal tonsil, in the midline is the pharyngeal bursa, an irregular flask-shaped 
depression of the mucus membrane.
World Health Organization (WHO) histopathological grading system describes three subtypes of 
nasopharyngeal carcinoma:
1. Keratinizing squamous cell carcinoma
2. Non-keratinizing differentiated carcinoma
3. Undifferentiated carcinoma (most common subtype)
Each of these subtypes appear more often in some areas of the world than in others. Only about 1 
in seven million people in North America are diagnosed with NPC, and of those diagnosed, 
about 1 in 4 cases are of the keratinizing type ( American Cancer Society, 2013 ). In China, it is 
mostly of the undifferentiated subtype.
NPC is most common in southeast China ( American Cancer Society, 2013 ), and is much more 
common in other parts of Asia, North Africa, the Inuit populations of Alaska and Canada, and 
the Chinese and Hmong immigrant groups in th e [LOCATION_002] (US), than in the general 
population.
Although it is not exactly understood what causes NPC, factors thought to predispose patients to 
this tumor include the presence of the Epstein-B arr virus (EBV), heavy alcohol and tobacco 
intake, a diet rich in salt-cured meats and fish, and a family history of NPC. The EBV appears in 
most NPC cells and is thought to be linke d although not completely elucidated. Patients with 
NPC have high levels of antibodies to EBV viral capsid antigen (VCA) and viral nuclear antigens. The presence of these antibodies is thought to precede the development of NPC by 
[CONTACT_72623]. The EBV infection has been s hown to decrease expression of tumor suppressor 
genes, which may help understand the carcinogenesis of NPC. In the clinical setting, EBV 
antibody or circulating viral deoxyribonucleic acid ( DNA) titers may be useful as a prognostic 
tool at diagnosis, and as a measure of tumor burden during treatment.&(/*(1([ZIP_CODE],(7$5<,1)250$7,21asal sal 
the lungs. the lungs.
upper surfaupper surf
sa of sa of 
harynx abuharynx abu
the mthe m uscleusclemmm
e pharyngeaharyng
an irren irre gulargula
system dessystem d
momon subtn subt yy
in soin so me me arear
ca are diaga are dia
zing tyzing ty pe peyyy(A
btype.btype.
heast Chinheast Chin
Asia, Northsia, North
g immigrang immigra
ot exactly uot exactly u
ludeudeththe pre p
et riet rich in sch in s
PC cells PC cells anan
have high have high
ttigens. Theigens. Th
several yeeveral ye
nesnes
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 17 CC-486-NPC-001 Final: 11 July 2014Heavy alcohol and tobacco intake are mostly associated with the keratinizing squamous cell 
carcinoma subtype. NPC also appears to be more common in males than in females, and in 
patients younger than 55 years of age ( American Cancer Society, 2013 ).
Thus, the multifactorial etiology implicates  genetic, viral, and environmental factors.
However, studies have shown that all subtype s derive from the epi[INVESTIGATOR_72592], and many NPCs also contain a high concentration of lymphocytes 
among the cancer cells. The presence of keratin has been associated with reduced local control and survival.
1.2. Diagnosis and Treatment
Nasopharyngeal carcinoma can be asymptomatic for long periods of time, which precludes early diagnosis. In most cases, the diagnosis is made based on locoregional advanced disease symptoms, with cranial nerve involvement or cervical node metastases ( Sham, 1993 ;Sham,
1990). Most patients present with stages III and IV with cervical node involvement at first clinical presentation. The most frequently reported location of metastasis is to bone (70% to 80%), followed by [CONTACT_72624] (liver, 30%; lung, 18%) and, at a decreased rate in axillary, 
mediastinal, pelvic, and inguinal nodes ( Ahmad, 1986).
Standard treatments for patients with NPC incl ude radiation therapy alone, concurrent 
chemoradiation followed by [CONTACT_72625], surgery for residual nodal disease, and chemotherapy alone for metastatic disease. High-dose radiation therapy with chemotherapy is the 
primary treatment of nasopharyngeal cancer, both for the primary tumor site and the neck ( Sham, 
1993).
Selected patients with local recurrence may be retreated with moderate-dose external-b eam 
radiation therapy using intensity-modulated radiati on therapy, stereotactic radiation therapy, or 
intracavitary or interstitial rad iation to the site of recurrence ( Baujat, 2006 ; Mendenhall, 2011 ; 
Vikram, 1985 ).
If a patient has metastatic disease or local recurrence that is no longer amenable to surgery or 
radiation therapy, chemotherapy should be considered ( Koutcher, 2010 ; Al-Sarraf, 1988 ;Jacobs, 
1992).
Therefore, chemotherapy remains an important treatment modality for palliative treatment and 
for metastatic NPC, especially those with a good performance status. Prognosis, especially for 
locally advanced stages (IIB â€“ IVB) and metastatic NPC remains poor: more than a third of cases 
will present with local and/or metastatic recurrence. In the recurrent metastatic disease setting, the median survival a nd progression-free s urvival (PFS) are even shorter, at approximately 8 to 
14 months and 4 to 6 months, respectively. Response rates (RR) range from approximately 14% to 38%. Isolated bone metastasis may be associated with long survival ( Ong, 2003 ). Overall, 5-
year survival for all NPC stages ranges from 50% to 70%. In first-line treatment of metastasis, 
platinum-based doublets, especially that of 5- fluorouracil (5-FU) and cisplatin, is generally 
recommended. In second line treatment of metastasis, the choice of chemotherapy depends on 
the previous treatment. In patients pretreated with platins, there is no established standard; 
reintroduction of platins depending on toxicity and the interval to recurrence: for an interval 
greater than [ADDRESS_78670] effective, with Ov erall Response (OR) 22% to 75%, but with associated ecludes earecludes ea
disease disease 
, 1993, 1993 ;;ShaSh
lvement atlvement at
s is to boneis to bo
d rate in axd rate in a
herapyherapy alalyyon
ryy ffyyor or ffresiresid
diiatatioion then th
r the primarr the primar
e retreated we retreated 
d radiation radiation
e site of ree site of
e or local re or local r
ppy shouly shoul d bd
pypyremains remainsyy
especially specially
stages (IIBstages (IIB
ith local anth local a
survival ansurvival an
hs and 4and 4 toto
%. %.IsolatedIsolated
ar survival r survival 
plplatatinuminum --bb
ecommecomm
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 18 CC-486-NPC-001 Final: 11 July 2014Grade 3 to 4 hematologic toxicity, which may limit its use. Second line capecitabine, 
gemcitabine or docetaxel monochemotherapy is r ecommended in cases of platin resistance (early 
[<6 months] recurrence) or in fragile subjects in whom toxicity could be threatening ( Foo, 2002 ).
However, a review of the literature on clinical trials for the treatment of metastatic NPC show that there is no consensus in second-line therapy or beyond and after progression with platins. 
Monotherapy with gemcitabine, capecitabine or ta xanes has been the most widely tested, with 
acceptable results ( Chan, 2010 ). In older studies, the most often used chemotherapy agents for 
monotherapy were methotrexate, bleomycin, 5- FU, cisplatin and carboplatin, with response rates 
of 15% to 31% ( Bensouda, 2011 ).  There were two Phase 2 studies that focused on metastatic 
NPC with two other drugs:  4-epi[INVESTIGATOR_72593] (a n anthracycline) and mitoxantrone, and the 
observed OR rates were about 20% ( Shiu, 1989 ; Dugan, 1993). In more recent clinical studies, 
other molecules such as gemcitabine, capecitabine, paclitaxel, docetaxel and irinotecan have 
been studies in patients pretreated with cisplatin ( Bensouda, 2011 ); gemcitabine and capecitabine 
had OR rates in the range of 23-48% and median survival between 7.2 and 14 months ( Foo, 
2002; Shiu, 1989 ; Ma, 2005 ; Chua, 2003 ; Chua, 2008 ; Ciuleanu, 2008 ; Zhang, 2008 ). The first 
study of weekly docetaxel in monotherapy for NPC was conducted in 2008 and reported similar results with an overall response rate (ORR) o f 37% and median survival of 12.8 months ( Ngeow, 
2011). All of the above-mentioned studies have been Phase 2 studies, mostly for pretreated patients, and for metastatic and recurrent NPC.
1.3. CC-486
5-Azacitidine (AZA), an analog of the pyrimidine nu cleoside cytidine, has effects on cell 
differentiation, gene expression, and DNA synthesis and metabolism, and causes cytotoxicity(Azacitidine Investigatorâ€™s Broc hure [IB]).
Vidaza
Â®(azacitidine injection) is approved by [CONTACT_3133] (FDA) for 
5 subtypes of the French-American British (FAB) classification system of myelodysplastic syndrome (MDS).  Vidaza is also approved by [CONTACT_72626], acute myeloid leukemia (AML) and c hronic myeolomonocytic leukemia (CMMoL)
patients who are not eligible for hematopoietic stem cell transplantation.  Vidaza can be administered by [CONTACT_33980] (IV) or subcu taneous (SC) routes as designated by [CONTACT_72627].
CC-486 is an orally bioav ailable formulation of AZA.
After its incorporation into a cellâ€™s DNA during the S-phase of the cell cycle, AZA forms 
covalent adducts with DNA Methyltransferase 1 (DNMT1) and depletes this enzyme required for 
the maintenance of DNA methylation patterns, thereby [CONTACT_72628][INVESTIGATOR_72594].  
Epi[INVESTIGATOR_72595] (DNA and histone proteins) that 
mediate the stable transmission of a geneâ€™s transcriptional status through cell division. One of the 
first recognized epi[INVESTIGATOR_72596]. The addition of a methyl 
group to cytosine in the dinucleotide (CpG) is catalyzed by [CONTACT_72629] (DNMTs) 
and is associated with transcriptional repression of genes with high density of CpGs (CpG 
islands) in the vicinity of their promoters (Miranda, 2007 ). Genomic methylation patterns are 
precisely regulated during normal embryonic development and differentiation and have been 
found to be altered in specific ways in cancer. Specifically, cancer cell genomes are typi[INVESTIGATOR_72597] &(/*(1([ZIP_CODE],(7$5<,1)250$7,21es es 
c c 
the he 
studistudi es, es, 
ecan have ecan have 
and capeciand capeci
months months ((FF
ang, 2008ang, 2008 ))
008 and rep008 and r
val oval o f f 12.812
ies, mes ostlyostly
ucleoside cycleoside
sis and metsis and m
d by [CONTACT_72630](FAB) (FAB
proved by[CONTACT_72631] b ty
mia (Amia (A MLL)
r hematopohematopo
 ((IVIV))or or su
iioavoavailaailableb
ratiration into on into 
cts wits wi thtiiiDNDh
nance of DNance of DN
tic changeschange
ate the stabate the sta
st recognist recogni zz
group to cgroup to c
nd is and is a
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 19 CC-486-NPC-001 Final: 11 July 2014genes encoding known tumor suppressors such as PTEN and BRCA1 as well as genes encoding 
proteins required for apoptosis, including caspase 8, DAPK and Apaf-1. DNA methylation-based 
silencing can thus contribute to the establishment and maintenance of the transformed state and 
limit the effectiveness of anticancer therapi[INVESTIGATOR_014].
CC-486 entered clinical testing in 2006 in subjects with MDS, CMMoL, and AML. The 
AZA PH US 2007 CL 005 study has shown that CC-486 is bioavailable and a maximal tolerated 
dose (MTD) of 480 mg daily for 7 days was defined based on dose- limiting dia rrhea at 600 mg
(Garcia-Manero, 2011 ).  As expected, reversible and manageable myelosuppression was 
observed.  Pharmacodynamic activity (DNA hypomethylation) and clinical responses were observed with CC-486, although the cross-over design (with SC Vidaza administered during 
Cycle 1) confounded the interpretation of these responses in Part 1 of the study.
The second part of the AZA PH US 2007 CL 005 study went on to explore both daily and twice
daily extended dosing schedules of 14 and 21 out of 28 days in a non-crossover fashion.  CC-486 administered 300 mg QD for 14 and 21 days of a 28-day cycle produces cumulative exposures 
(area under the concentration curve [AUC] per cycle) that are approximately 40% and 60% of 
the exposure achieved with the labeled dose and schedule of Vidaza, respectively. Daily doses of 
[ADDRESS_78671] proven to be tolerated on both the 14 and 21 out of 28-day schedules with 
myelosuppression, gastrointestinal (GI) symptoms, a nd fatigue being the most common toxicities 
(Garcia-Manero, 2011 ).
In the AZA PH US 2007 CL 005 study , DNA methylation levels in  blood were measured as a 
pharmacodynamic (PD) endpoint, to determine DNA hypomethylating activity of CC-486.  In 
summary, it was confirmed that CC-486 is biologically active, reducing DNA methylation when 
administered at low doses on extended schedules.
1.3.1. CC-486 Experience in Solid Tumors
A Phase 1 study of CC-486 in combination wi th carboplatin and nab-paclitaxel, or as a single 
agent in subjects with relapsed or refractory  solid tumors (AZA-ST-001) was initiated on 
30 Nov 2011.  In Part 1 of this two-part study, CC-486 at escalating doses of 200 or 300 mg was 
administered on Days 1 to 14 of a 21-day cycle in three separate arms of the study (Arm A, Arm B, Arm C).
In Arm A of AZA-ST-001, subjects received carboplatin (AUC = 4) on Day 8 of each cycle and 
in Arm B, subjects received nab-paclitaxel 100 mg/m
2beginning on Day 8. For Arm A, both 200 
mg and 300 mg were well tolerated with carboplatin AUC = 4.  For Arm B, initially, nab-
paclitaxel was administered weekly starting on Cycle [ADDRESS_78672] dose level of CC-486. The protocol was amended to give nab-paclitaxel on Days 8 and 15 of each cycle (ie, 2 out of 3 weeks) and this was well tolerated 
in combination with CC-486 at 200 mg. When the CC-486 dose was escalated to 300 mg, dose-limiting ne utropenia was again encountered, making the 200 mg the MTD of CC-486 in 
combination with nab-paclitaxel 100 mg/m
2on a 2- out of 3-week schedule. Arm C of Study
AZA-ST-001 assessed the safety of continuous administration of CC-486 on a 21- out of 21-day &(/*(1(35235nnSSolid olidTTu
n combinatn combinat
psed or refed or ref
of this twoof this tw
ys [ADDRESS_78673]-0-0
subjects reubjects re
300 mg w300 mg w
itaxel was aitaxel was 
ncounteredncountered
nab-napaclipacli
comcom5,(7$5<,1)250$7,21ring ng 
ailyilyand twand twy
fashiofashio n.  n.C
mulatmulat ive exive e
telyely40%40% an
espectespect ivelyivel
dayayscscyyhedh
being the mbeing the m
n n leleveels lsin ib
hypohypo metmethyhy
aally actlly act ive,ve
.
5,(35,
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 20 CC-486-NPC-001 Final: [ADDRESS_78674] -001 were observed on Arm B. Of 8 evaluable 
subjects with relapsed pancreatic carcinoma, one had a partial response (PR) and 3 others had 
stable disease (SD) > [ADDRESS_78675] by [INVESTIGATOR_6875]-486.
1.3.2. CC-486 in Nasopharyngeal Carcinoma (NPC)
Limited data exists with CC-[ADDRESS_78676] shown a partial response (PR) [1 not yet confirmed], and [ADDRESS_78677] had received 2 prior anticancer regimens and remained on CC-486 treatment for 370 days.
Please refer to th e Azacitidine IB for detailed information concerning the available 
pharmacology, toxicolo gy, drug metabolism,  clinical studies, and adverse event (AE) profile of 
azacitidine/CC-486.
1.4. Rationale
CC-486 as a single agent has shown promising activity in NPC subjects in a Phase 1 clinical trial
with durable responses. CC-486 was tolerated in subjects when used at the dose of 300 mg daily for 14 days out of 21-day cycle with a manageable safety profile.
As an epi[INVESTIGATOR_72598], it is hypot hesized that CC-486 will lead to immune-mediated 
antitumor effects in subjects with NPC. The use of epi[INVESTIGATOR_72599]:
!Frequent wide-spread methylation of cancer-related genes in NPC ( Lo, 2013 ).
!Genetic abnormalities and EBV play major role in pathogenesis of NPC.
!NPC is strongly associated with EBV infection ( Thompson, 2007 ), with DNA 
methylation playing an important role in  the maintenance of specific EBV latency 
programmers and regulating EBV lifecycle and latency in NPC cells ( Paulson, 1999 ; 
Tierney, 2000 ; Salamon, 2001 ; Zhang, 2012a ). &(/*(1([ZIP_CODE],(7$5<,1)250$7,21aluable uable 
hers had hers had
in subjectsn subject
ovocative, ovocativ
ZAZ-STST-00-[ADDRESS_78678] reprep
re encouragre encoura
86 treatmen86 treatme
informatinformat ioio
sm, clinicalsm, clinical
shown proshown pro
C-486 w486 w as 
ayaycycle wicycle w
odifying agdifying a
ssin subjectin subjec
pportedpported in tin t
FrequentFreque
!GenGen
!!
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 21 CC-486-NPC-001 Final: 11 July 2014!Promoter hypermethylation is a major mechanism for inactivation of critical tumor 
suppressor genes ( p16,RASSF1A) ( Lo, 2013 ).
!DNA CpG methylation is associated with silencing of EBV immunodominant 
antigens and tumor suppressor genes ( Robertson, 1997 ; Okada, 2013 ).
âˆ€May inhibit the tumorgenicity of EBV-infected cells
In addition, epi[INVESTIGATOR_72600] ( Kenney , 2014).
!Viral lytic reactivation via demethylation may provide a path to targeting EBV-associated tumors.
!Azacitidine induces demethylation of the EBV genome in tumors ( Chan, 2004 ).
!DNA methylation inhibitors can reverse chemoresistance and prevent the development of acquired drug resistance ( Zhang, 2012b ).
No standard of care options exist for patients with NPC in second and third line settings.
In a Phase 1 study of Japanese subjects treated at a dose of 300 mg QD for 21 days of 28-day 
cycle, all evaluable subjects (4 out of 5) exper ienced Grade 3-[ADDRESS_78679] of care, and the encouraging yet immature data in the Phase 1 
study warrant further evaluation of CC-486 as a single agent to confirm the activity of the drug 
in subjects with NPC.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21, 2004, 2004 ).).
nt the nt the 
ird diline setline 
QD for 21 D for 21 
neutropeniautropeni
daydayschedusche
proposal isroposal 
200 mg da200 mg d
creasing thcreasing th
l be fol be fo llollow
NPC who NPC who 
d the encouthe encou
86 as 86 as a a sins
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 22 CC-486-NPC-001 Final: 11 July [ZIP_CODE]. STUDY OBJECTIVES
2.1. Primary Objectives
The primary objective of this study is to evaluate the efficacy of CC-486 in subjects with NPC.
2.2. Secondary Objectives
The secondary objectives of this study are to evaluate safety in all subjects and pharmacokinetics
(PK) of CC-486 in a subset of subjects of As ian-Pacific Island ethnicity at experienced selected 
sites.
2.3. Exploratory Objectives
 
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21neteticsi
lected ected 
)251)2
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 23 CC-486-NPC-001 Final: 11 July [ZIP_CODE]. STUDY ENDPOINTS
3.1. Primary Endpoints
The primary endpoints are:
!Overall response r ate (ORR) defined as the combined  incidence of complete response 
(CR) and PR, confirmed no less than [ADDRESS_78680] 
met, based on independent radiology assessment using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, AND
!Progression-free survival (PFS) measured as t ime from the start of the study tr eatment 
to progression based on an independent radiology assessment of response using RECIST v1.1.
3.2. Secondary Endpoints
The secondary endpoints include:
!Overall survival (OS) defined as the time from first treatment to death by [CONTACT_55544]
!Safety to include the incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), Grade 3- [ADDRESS_78681], and laboratory abnormalities and other safety parameters
!Pharmacokinetics (PK) of CC-486 in a subset of subjects of Asian-Pacific Island ethnicity at experi enced s elected sites
3.3. Exploratory Endpoints
 
 
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21erieria a
dydytreatmtreatmy ee
nse using se using 
eatment to tment to
rgent adverrgent adve
s, , Grade Grade 3 a3
normalitiesnormalities
subset of subset of
ss
23552335(3
(1(*(1
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 24 CC-486-NPC-001 Final: 11 July [ZIP_CODE]. OVERALL STUDY DESIGN
4.1. Study Design
This is a Phase 2, single arm, multicenter, inte rnational study to assess the safety and efficacy of
single agent CC-486 (oral azacitidine) in previously treated subjects with locally advanced or 
metastatic nasopharyngeal carcinoma, who have progressed (clinically or radiographically) after 
having received 1 to 2 previous regimens, including a platinum agent. The co-primary endpoints 
are ORR and PFS.
Approximately 51 to 55 efficacy evaluable subjects will be enrolled according to Simonâ€™s 
optimal two-stage design; if the predefined activit y is met (> 4 responses [CR/PR] out of the first 
17 efficacy evaluable sub jects based on independent radiological assessment), then the study will 
continue to enroll an additional 34 efficacy evaluable subjects. If â‰¤ [ADDRESS_78682] v1.1 initially every 6 weeks (Â± 5 days) 
and then according to Section 6.2until documented disease progression, start of new anticancer 
therapy, withdrawal of consent, or lost to follow-up. All subjects will also be followed for 
survival and subsequent anticancer therapi[INVESTIGATOR_014].ioio$5<,1)250$7,21ntts s
nâ€™s ns
ut of the fiut of the f
en en ththe stude stud
es out of 17es out of [ADDRESS_78683] vv1.1 1 initii t
d d disease pdisease p
w--upup. All su. All 
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 25 CC-486-NPC-001 Final: 11 July 2014Figure 1: Study Design
Screening
Subjects â‰¥  [ADDRESS_78684] treatment follow-up
28 day safety follow-up
Tumor evaluation according to protocol until 
progression or new cancer therapy
Survival follow-up until deathIf  > 4 
subjects with 
CR/PR, 
continue.Eligibility check
Positive if 
>14 CR/PR 
total  or     
Median PFS 
> 5 months  Treatment
CC-486 300 mg daily
(CC-486 200 mg daily in 1st6 Asian-Pacific  
Island  Ethnicity Subjects for safety) 
for Days 1-14, of [ADDRESS_78685] imated median 
survival for the entire enrolled population of approximately 8 to 10 months. All subjects will be 
followed for safety and monitoring of adverse events (AEs) for [ADDRESS_78686] dose of IP, 
for response until progression (if applicable), and for new anticancer therapi[INVESTIGATOR_72601], or the End of Trial (as defined in Section 4.3), whichever occurs 
earlier.
4.3. End of Trial
The End of Trial is defined as either the date of the last visit of the last subject to complete the study, or the date of receipt of the last data point from the last subject that is required for 
primary, secondary, and/or exploratory analysis, as pre-specified in the protocol and/or the 
Statistical Analysis Plan, whichever is the later date. If â‰¤ 4 responses out of 17 efficacy evaluable 
subjects are observed in Stage 1, then the study enrollment will be stopped.&(/*(1([ZIP_CODE],(7$5<,1)250$7,215,(7$5<,1)250$7   
FS 
month1)
tmtment is exent is e
populationpopulatio
niitoritoriiing of ng o
ssiossn (if apn (if 
r analysis, r analysi
nd of Trind of Tri
of Trial is Trial i
or the dateor the date
marymary , secon, seco
StatiStatistical ical AA
subjectsubject
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 26 CC-486-NPC-001 Final: 11 July [ZIP_CODE]. TABLE OF EVENTS
Table 1: Table of Events
Screening 
Period Treatment PeriodaFollow-up Period
Events Screening Cycle 1 Cycle 2Subsequent 
cycles
Day -21 to -1 1b14 1 1 EOTDisease 
Progression/ 
Survival
STUDY ENTRY
Informed consent X --- --- --- --- --- ---
Prior cancer history X --- --- --- --- --- ---
Prior cancer therapi[INVESTIGATOR_014] X --- --- --- --- --- ---
Complete medical history X --- --- --- --- --- ---
Demographics X --- --- --- --- --- ---
IRT [registration/IP accountability only]X As needed
Prior/ concomitant medication 
evaluationcX(â‰¤28d from 
screening)Continuous, until 28 days after treatment discontinuation
Prior/ concomitant procedures 
evaluationdX(â‰¤28d from 
screening)Continuous, until 28 days after treatment discontinuation
Inclusion/exclusion criteria X --- --- --- --- --- ---
SAFETY ASSESSMENTS
Adverse event evaluation Continuous starting after informed consent signature, until 28 days after treatment discontinuation
&(/*priprietet/*(1([ZIP_CODE],(7$5<,1)250$7,21e Corporae Corpora
21
0$
quent en
eses25252525
11)2
<,<<<---5<$-----$$$57$----7$7$7$7$
------(75,----5,5,5,5,As neededs neede3555
52ContiConti52525252
8ddfrom m
eening)eening)3
XX1(((((1CC*(*(*(/**(
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 27 CC-486-NPC-001 Final: 11 July 2014Table 1: Table of Events (Continued)
Screening 
Period Treatment PeriodaFollow-up Period
Events Screening Cycle 1 Cycle 2Subsequent 
cycles
Day -21 to -1 1b14 1 1 EOTDisease 
Progression/ 
Survival
Physical examination (source documented only)X X --- X X X ---
Weight X X --- X X X ---
Height X --- --- --- --- --- ---
Vital signseX X --- X X X ---
Hematology laboratory X X X X X X ---
Chemistry laboratory X X --- X X X ---
Epstein-Barr Virus-DNA [by [CONTACT_937]-PCR] 
in All SubjectsX X --- X X --- ---
Coagulation (Baseline only) X --- --- --- --- --- ---
UrinalysisfX X --- X X X ---
12-lead electrocardiogram X --- --- --- --- X ---
Serum Î²-hCG (for all FCBP)gX --- --- --- --- X ---
Urine Î² -hCG (for all FCBP)gX(w/in72 hours) X --- X X X ---
&(/*(1(priprietet1((w/in72 houw/in72 ho( [ZIP_CODE],(7$5<,1)250$7,21e Corporae Corpora
21
FoFollo777,2$70$5
EE55555025
XX1)
<,XX<,<,<,<, ----5<<<<
XX$57$XX7$7$7$7$-----(777
5,7
----5,5,5,(5,
----35
XX2252--525252523555
(1(
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 28 CC-486-NPC-001 Final: 11 July 2014Table 1: Table of Events (Continued)
Screening 
Period Treatment PeriodaFollow-up Period
Events Screening Cycle 1 Cycle 2Subsequent 
cycles
Day -21 to -1 1b14 1 1 EOTDisease 
Progression/ 
Survival
EFFICACY ASSESSMENTS
Tumor evaluation (CT/MRI) X( â‰¤28d to -1) Every 6 weeks (Â± 5 days) from Cycle [ADDRESS_78687] three tumor evaluations 
and then every 9 weeks until disease progression or start of a new anticancer treatment, or withdrawal of consent
ECOG performance status X X --- X X X ---
BIOMARKER AND PK ASSESSMENTS
Plasma for Epstein-Barr Virus-DNA XhXh--- X (Xi), C3, 5, 
and 7 only---
HBV and HCV titers (for subjects of A-P ethnicity only)X --- --- --- --- X ---
Tumor biopsy* (for Biomarkers) Xh,jXh,j--- X --- ---
PK blood draws sampling --- X** X** --- --- --- ---
INVESTIGATIONAL PRODUCT (IP)
Administer CC-486 Daily on Days 1-14 Daily on Days 1-14Daily on Days 1-14
IP accountability --- X --- --- X --- ---
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21e Corporae Corpora
21
priprietetFoFollo777,2$70$5
EE55555025
1) Cycle 1 Dayycle 1 Da
disease progdisease pro
f consentf consent,1
XX5<$ASSESSMEASSESS$$$
-----(7$7$7$
5,7
------5,5,5,(5,
XXh,jhj2352X**X**52525252 INVESTINVES35553
-----1(((((1
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 29 CC-486-NPC-001 Final: 11 July 2014Table 1: Table of Events (Continued)
Screening 
Period Treatment PeriodaFollow-up Period
Events Screening Cycle 1 Cycle 2Subsequent 
cycles
Day -21 to -1 1b14 1 1 EOTDisease 
Progression/ 
Survival
FOLLOW-UP
Survival follow-up --- --- --- --- --- --- Every 8 weeks (+/- 5 days)
Anticancer therapy since IP discontinuation--- --- --- --- --- --- At every survival follow-up visit
A-P = Asia-Pacific; Î²-hCG = beta subunit of human chorionic gonadotropin; CT = computed tomography; d = day; DNA = deoxyribonucleic acid; ECOG =
Eastern Cooperative Oncology Group; EOT = end of treatment; FCBP = female of childbearing potential; FFPE = formalin-fixed, paraffi n-embedded; HBV =
hepatitis B virus; HCV = hepatitis C virus; IP = investigational pr oduct; IRT = interactive response technology; MRI = magnetic resonanc e imaging; PK =
pharmacokinetics; RT-PCR = real time polymerase chain reaction; w/in = within.
* Refer to Section 6.5, Table 3 .
** Refer to Section 6.4, Table [ADDRESS_78688] a Â± 2-day window, except Cycle [ADDRESS_78689] occur within 21 days from Informed Consent Form signature.
bCycle 1 Day 1 evaluations can be omitted if screening evaluations are performed within 72 hours of Cycle 1 Day 1.
cPrior/concomitant medication evaluation â‰¤ [ADDRESS_78690] dose.
dPrior/concomitant procedures evaluation â‰¤ [ADDRESS_78691] be recorded in the database at screening and EOT only, and kept in the source documents at all oth er visits.  However, if an 
abnormal (out of range) value is reported at a given visit, that parameter should be collected in the case report form (CRF) at  every subsequent scheduled visit 
until it returns to normal.
f Urinalysis (a urine dipstick may be used) at screening and D1 of each cycle if abnormal at baseline.
gSerum Î²-hCG (for all FCPB) performed at screening; remaining pregnancy tests may be serum or urine at the Investigatorâ€™s discretion. P regnancy testing (for 
all FCPB) must be done within [ADDRESS_78692] 
is performed > [ADDRESS_78693] is negative.
hSample can be collected during screening or pre-dose Cycle 1 Day 1; being done in Stage 1 subjects only. [STRONGLY encouraged/re commended]
iSample is collected at Cycle 3 Day 1, Cycle 5 Day 1, and Cycle 7 Da y 1; being done in Stage 1 subjects only. [STRONGLY encouraged/recommended]
jArchival FFPE sample can be submitted for the screening or pre-dose Cycle 1 Day 1 timepoint.
&(/priprietet(/*(1([ZIP_CODE],(7$5<,1)250$7,21e Corporae Corpora
21
FoFollo777,2$70$5
EE55555025
1)------,,,1<, ----5<<<
$$$$<
mputed tomomputed to
childbearing childbearing
teractive eractiv re
hinhin.
ust occur witust occur
ons are perfos are perfo
irst treatmentrst treatmen
e first treatme first treatm
base at screenase at scre
visit, that pavisit, tha
creening and reening and
screening; rescreening; re
s prior to the s prior to the 
dose, a urine se, a urine 
negative.egative.
screening oreening o
3 Day3 Da  1, Cy, Cyy
n be submittn be submitt
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 30 CC-486-NPC-001 Final: [ADDRESS_78694] eligibility, but may be repeated within the screening window if 
necessary.
The following will be performed at screening as specified in the Table of Events ( Table 1 ), after 
informed consent has been obtained:
!Cancer history (including specific information regarding diagnosis, staging, 
histology)
!Demographics (initials, date of birth, sex, race, and ethnicity-if allowed by [CONTACT_427])
!Interactive response technology (IRT) for subject number registration and IP accountability only
!Prior cancer therapi[INVESTIGATOR_014]: includes surgery, radiation, systemic or any other therapy for the subjectâ€™s cancer
!Complete medical history (all relevant medical conditions occurring â‰¥28 days before 
screening should also be included)
!Prior and concomitant procedures (including all procedures occurring â‰¤28 days 
before screening)
!Prior and concomitant medication ev aluation (including those taken â‰¤28 days before 
screening, except for those taken for cancer)
!Physical examination (source documented only), height, weight
!Vital signs (including blood pressure, temperature, and heart rate)
!Eastern Cooperative Oncology Group (ECOG) Performance status ( Oken, 1982 ) see 
Appendix A
!12-lead electrocardiogram (ECG)
!Response assessment/ tumor evaluation (see Section 6.3). Subjects with historical 
tumor scans evaluable per RECIST 1.1 performed â‰¤ [ADDRESS_78695] dose 
need not repeat scans for the purposes of screening
!Complete blood count (CBC) with differential,  including but not limited to red blood 
cell (RBC) count, hemoglobin, hematocrit, white blood cell (WBC) count, absolute &(/*(1([ZIP_CODE],(7$5<,1)250$7,21toryry
ndow if dow if 
((TableTable 11),)
nosiosis, stagins, stagin
niciticy-y-if allif al
ct number rnumber r
radiradiatation, sn
vant medicvant medic
ded)ded)
cedures (incedures
ant mnt medicaedic
pt for those t for thos
aminatamina ion (n
gns (includgns (includ
stern Coopetern Coop
Appendix AAppendix A
!12-2-leadlead
!!ReRe
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 31 CC-486-NPC-001 Final: 11 July 2014neutrophil count (ANC), and platelet count. ANC should be measured with automated 
count where available
!Chemistry panel including, but not limited to, sodium, potassium, calcium, chloride, blood urea nitrogen (BUN), creatinine, glucose, albumin, total protein, alkaline phosphatase, bilirubin (total and direct), aspartate aminotransferase/serum glutamic oxaloacetic transaminase (AST/SGOT), alanine aminotransferase (ALT/SGPT)
!Epstein-Barr Virus-DNA [by [CONTACT_72632]-polymerase chain reaction (RT-PCR)] in all subjects
!Tumor biopsy: Sample can be collected during screening or pre-dose Cycle 1 Day 1
!HBV and HCV titers (Asian-Pacific ethnicity subjects only)
!Plasma for Epstein-Barr Virus-DNA (Stage 1 subjects only; refer to Section 6.5): 
Sample can be collected during scre ening or pre-dose Cycle 1 Day 1
!Coagulation tests including, prothrombi n time (PT), partial thromboplastin time 
(PTT), international normalized ratio (INR)
!Urinalysis (a urine dipstick may be used) at screening (and D1 of each cycle if abnormal at baseline)
!Pregnancy test is required for all female subjects of childbearing potential.  Serum Î²-hCG pregnancy test will be performed at screening. Urine (or serum) pregnancy 
test will be performed to assess subject e ligibility within [ADDRESS_78696] did not already occur with 72 hours 
of dosing (negative results required for IP administration)
!Adverse event assessment begins after the subject signs the informed consent form
Day [ADDRESS_78697] start 
treatment within 21 days of signing the informed consent form (ICF). For all subsequent visits, 
an administrative window of Â± 2 days is permitted.
Treatment cycles are 21 days in duration, and will occur as described in Section 8.2.
The following evaluations will be performed at the frequency specified in Table 1 , Table of 
Events. The evaluations should be performed prior to dosing on the visit day, unless otherwise 
specified:
!Concomitant medications evaluation
!Concomitant procedures evaluation
!Physical examination (source documented only)
!Vital signs: on-treatment vital sign measurements will be source documented only.  
However, if an abnormal (out of range) valu e is reported at any given visit, that &(/*(1([ZIP_CODE],(7$5<,1)250$7,21DayDay 11y
ectiection on6.565
y 1y
romboplastombop
(and D1 of and D1 of
ts of of childbchild
creening. Ucreening. 
igibilitigibilit y y wi
nancy test dnancy test d
for IP admfor IP adm
ns safafter ter fffththee
omimitted if Stted if ii
odod
atment upoatment 
ys of signinys of signin
indow of Â±dow of Â±
es are 21 daes are 21 da
ing evaluatng evaluat
The evaluatevalua
fied:fied:
!C
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 32 CC-486-NPC-001 Final: 11 July 2014parameter should be collected in the case report form (CRF) at every subsequent 
scheduled visit until it returns to normal, and as an AE if appropriate.
!Weight
!Complete blood count with differential
!Chemistry panel
!Epstein-Barr Virus-DNA [by [CONTACT_72633] (RT-PCR)] in all 
subjects
!PK sample (only being done in 6 subjects of Asian-Pacific ethnicity at 200 mg dose initially; then in an additional 6 if dose is escalated to 300 mg dose) (see Section 6.4)
!Tumor biopsy [STRONGLY encouraged/recommended] (Only being done in Stage 1 subjects) (see Section 6.5)
!Plasma for Epstein-Barr Virus-DNA (Stage 1 subjects only)
!ECOG Performance status ( Oken, 1982 ) see Appendix A
!IRT for IP accountability
!Adverse event evaluation (continuously)
!Response assessment/tumor evaluation (see Section 6.3)
!Urine (or serum) Î² -hCG pregnancy test (prior to dosing on Day 1)
!Urinalysis (at screening and D1 of each cycle if abnormal at baseline)
6.1.1. End of Treatment
An end of treatment (EOT) evaluat ion should be performed for s ubjects who are withdrawn from 
treatment for any reason as soon as possible af ter the decision to permanently discontinue 
treatment has been made. Subjects should also be discontinued through the IRT system.
The following evaluations will be performed as specified in the Table of Events ( Table 1 ):
!Physical examination (including weight)
!Vital signs
!Concomitant medications evaluation
!Concomitant procedures evaluation
!ECOG performance status ( Oken, 1982 ) see Appendix A
!IRT for IP accountability
!Adverse event evaluation (monitored through [ADDRESS_78698] dose of IP)
!Complete blood count (with differential)
!Chemistry panel
!HBV and HCV titers (Asian-Pacific ethnicity subjects only)&(/*(1([ZIP_CODE],(7$5<,1)250$7,21g dose dose 
ecctition on 6.46.4))
done in Staone in Sta
ectction n6.36.3))
pririor to dosior to dos
ch cycle if h cycle if 
houlhould be pd be 
possible aftossible a
s should als should a
ll be perforll be perfor
minatminat ioionn(in
nss
omitant meomitant m
ConcomitanConcomitan
ECOG ECOG
!!IRTIRT
!!
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 33 CC-486-NPC-001 Final: 11 July 2014!Urine (or serum) Î² -hCG pregnancy test for females of childbearing potential
!Response assessment/ tumor evaluation will be continued at the schedule defined in 
the Table of Events, and does not need to be performed specifically for the EOT visit 
except as specified in Section 6.3.
!12-lead ECG
!Weight
!Urinalysis
6.2. Follow-up Period
6.2.1. Efficacy Follow-up
All subjects who discontinue treatment for reasons other than disease progression, start of new 
anticancer therapy, or withdrawal of consent from the entire study will be followed for tumor 
response assessments and subsequent anticancer therapi[INVESTIGATOR_72602] 6.3.
6.2.2. Survival Follow-up
After the EOT visit, all subjects will be followed every 8 weeks (Â± 5 days) for survival until
withdrawal of consent, death, or lost-to-follow up, whichever occurs first. Subsequent anticancer 
therapi[INVESTIGATOR_72603].  New anticancer therapy includes (but is not 
limited to) any systemic or local medication, surgery , radiation, or any other therapy intended to 
treat the subjectâ€™s cancer.
Survival follow-up may be conducted by [CONTACT_72634] (including public records) and/or 
telephone contact [CONTACT_1155], family, or the subjectâ€™s treating physician.
6.3. Response Assessments
Response assessments (tumor evaluations) shoul d be performed at screening within 28 days 
before the start of IP, and every 6 weeks (Â± 5 days) from Cycle [ADDRESS_78699] v1.1 performed â‰¤ [ADDRESS_78700] v1.1, according to Investigator assessment.  Response 
assessments include computed tomography (CT) scan or magnetic resonance imaging (MRI) of 
the head and neck with supraclavicular node imaging, the chest and abdomen/pelvis, 
neurological examination with facial nerve evaluation, and bone scans at baseline for all 
subjects. Bone scans will be repeated only if the subject is symptomatic or with known bone metastasis .&(/*(1([ZIP_CODE],(7$5<,1)250$7,21sion, start osion, start o
oollollowed fowed fo
n Section Section 6
s (Â± 5 day(Â± 5 d
er occurs fir occurs fi
w anticanceranticanc
radiatiradiati on, on, 
d review (ireview (
or ther the subjesubje
s
luatluatioions) shs) 
y66yweeks (weeks (
weeks weeks unu
from the efrom th
formed ormedâ‰¤ 288
ng.ng.EvaluaEvalua
vestvestigatorigator
dent dent radioradio lolo
AssessAssess
esponse wilsponse wil
assessmenssessmen
hhe heade hea
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 34 CC-486-NPC-001 Final: [ADDRESS_78701] should be 
performed by [CONTACT_2363] a 5 mm c ontiguous reconstruction algorithm.
All subjects with evidence of objective tumor response (CR or PR) should have the response confirmed with repeat assessments at the next scheduled scan, but after no less than [ADDRESS_78702] occurred â‰¥ [ADDRESS_78703] response.
[IP_ADDRESS]. Other Assessments
Subjects who are symptomatic for brain metastasis at screening must undergo a brain scan to 
confirm eligibility. All subjects must undergo bone scans at baseline.
6.4. Pharmacokinetics
A subset of enrolled subjects (Asian-Pacific island ethnicity only) at a selected number of experienced sites that have the ability to collect, process, and ship CC-486 PK samples will 
participate in PK sample collection. Six subjects of Asian-Pacific island ethnicity initially being 
administered 200 mg CC-486 on Days 1-14 of a 21-day cycle will be asked to participate in the 
PK sample co llection at these selected sites. An additional 6 subjects of Asian-Pacific ethnicity
will participate in the PK sampling if the dose is escalated to 300 mg in this population.
On each PK day (ie, Cycle 1 Days 1 and 14), subjects will ingest IP in the clinic after performing 
the required overnight fasting, if applicable tak ing antiemetic premedication (eg, odansetron), 
and completing the required pre-dose assessments (where applicable), with each dose being 
given at approximately the same time of day.  The exact
date and time of dosing will be recorded 
in the source documents and appropriate CRF.
Blood samples for oral azacitidine PK a ssessment will be collected prior to each dose 
administration (pre-dose) and over the 8-hour period following each dose administration (0.25, 
0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and [ADDRESS_78704]-dose or similar schedule) (see Table 2 ).
Table 2: Schedule of Pharmacokinetic Blood Sample Collection in the 
Pharmacokinetics Phase
Nominal Times Acceptable Deviation Window
Pre-dose â‰¤ 60 min
0.25 hr Â± 3 min
0.5 hr Â± 3 min
1 hr Â± 3 min
1.5 hr Â± 3 min
2 hr Â± 3 min
2.5 hr Â± 3 min&(/*(1([ZIP_CODE],(7$5<,1)250$7,21as SD s SD 
a brain scabrain sc
)at a selat a sel ectect
ship CChip CC -48
acific acific islanislan
cycle will by[CONTACT_72635]6 subj6 subj
scalated to scalated to 
ubjects wilubjects wi
taking anttaking ant ii
sessments (sessments (
of day.  Thof day.
priate CRFiate CRF
ine PK assne PK ass
nd over the d over th
4, 6, and 84, 6, and
dule of Phaule of Ph
armacokinrmacokin
NominaNomina(1*(/*(/&(&
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 35 CC-486-NPC-001 Final: 11 July 2014Table 2: Schedule of Pharmacokinetic Blood Sample Collection in the 
Pharmacokinetics Phase (Continued)
Nominal Times Acceptable Deviation Window
3 hr Â± 3 min
3.5 hr Â± 3 min
4 hr Â± 3 min
6 hr Â± 20 min
8 hr Â± [ADDRESS_78705] 8 hours, all required pre-dose assessments and procedures 
(including obtaining the pre-dose PK sample) should be performed.  Then, if applicable, subjects should ingest antiemetic premedication (e g, odansetron) with [ADDRESS_78706]-dose.  Water can be allowed 
as desired except for 1 hour before and after CC- 486 administration.  The only water permitted 
in the 1-hour period before CC-486 administra tion is the 240 mL of water for antiemetic and IP
ingestion.
6.5. Biomarkers
 
 
 
 
Biomarkers will 
be assessed for Stage 1 subjects only.  
 
 &(/*(1(1(1(1(1((1111
*(352ts onlyonly.,(7$5<,1)250$7,[ZIP_CODE]$7$7$70$$[ADDRESS_78707]-dose.
trationtratio .  ThT
40 mL of w mL of 
5,(35,23523525235(31(1
(/&
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 36 CC-486-NPC-001 Final: [ADDRESS_78708] satisfy the following criteria to be enrolled in the study:
1. Subject is â‰¥[ADDRESS_78709] has an ECOG performance status 0 to 2. ( Oken, 1982 ) see Appendix A
6. Subject has radiographically-documented measurable disease, as per RECIST 1.1.7. Subject has adequate organ functions, evidenced by [CONTACT_716]:
a. AST (SGOT), ALT (SGPT) â‰¤ 2.5 x upper limit of normal range (ULN), or â‰¤ [ADDRESS_78710]
range if liver metastasis present
b. Total bilirubin â‰¤ 1.[ADDRESS_78711]
c. Creatinine â‰¤ 1.[ADDRESS_78712] has adequate bone marrow function, evidenced by [CONTACT_716]:
a. Absolute neutrophil count â‰¥ 1.5 x 10
9 cells/L
b. Platelets â‰¥ 100 x 109cells/L
c. Hemoglobin â‰¥ 9 g/dL
9. Females of childbearing potential (FCBP) (defined as a sexually mature woman who 1) 
has not undergone a hysterectomy (the surgical removal of the uterus) or bilateral 
oophorectomy (the surgical removal of both ovaries) or, 2) has not been naturally 
postmenopausal for at least 24 consecutive months  (ie, has had menses at any time during 
the preceding 24 consecutive months) must:
a. Have two negative pregnancy tests as verified by [CONTACT_72636]: negative serum pregnancy test, sensitivity of at least 25 mIU/mL at 
screening AND have a negative serum or urine pregnancy test within 72 hours prior 
to starting study therapy (note that the scr eening serum pregnancy test can be used as 
the test prior to starting study therapy in the treatment phase if it is performed within the 72-hour timeframe). She must agree to ongoing pregnancy testing during the &(/*hh/*(1([ZIP_CODE],(7$5<,1)250$7,21ument.ument.
poorlypoorly
mmetastatietastati c.c
llyyafafter tefff1 t
n, 1982n, 1982 ) se) 
abble diseasele diseas
ced by[CONTACT_72637], or corange, o
e marrow fue marrow 
hil count hil count â‰¥ â‰¥
x 10109cellscells
â‰¥ 9 g/dLâ‰¥ 9 g/dL
childbearinchildbearin
undergone aundergone 
orectomyrectomy (th(tyy
stmmenopausenopaus
e precedpreced i
a.a.HaHa
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 37 CC-486-NPC-001 Final: [ADDRESS_78713] practices true abstinence
*from heterosexual contact.
b. Either commit to true abstinence*from heterosexual contact (which must be reviewed 
on a monthly basis) or commit to use, and be able to comply with effective 
contraception (oral, inj ectable, or implantable hormonal contraceptive; tubal ligation;
intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner)without interruption, 28 days prior to starting IP, during the study therapy (including 
dose interruptions), and for [ADDRESS_78714] co mmit to true 
abstinence
*from heterosexual contact [CONTACT_72638], and avoid fathering a child during the course 
of the study (including dose interruptions) and for [ADDRESS_78715] understands and voluntarily signs an ICF prior to any study-related 
assessments/procedures are conducted.
12. Subject is able to adhere to the study visit schedule and other protocol requirements.
7.3. Exclusion Criteria
The presence of any of the following will exclude a subject from enrollment:
1. Subject has a history of, or current brain metastasis. In subjects who are symptomatic, a 
brain scan is required to exclude metastasis.  Primary NPC tumors that are 
touching/penetrating the skull are not considered brain metastasis.
2. Subject has any other malignancy within 5 years prior to randomization, with the 
exception of adequately treated in situ carcinoma of the cervix, uteri, or non-melanomatous skin cancer (all treatment of which should have been completed 6 months 
prior to enrollment), in situ squamous cell carcinoma of the breast, or incidental prostate 
cancer T1a, Gleas on < 7, PSA <10 ng/ml.
3. Subject has been previously tr eated with azacitidine (any formulation), decitabine, or any 
other hypomethylating agent.
4. Subject has a history of inflammatory bowel disease (eg, Crohnâ€™s disease, ulcerative 
colitis), celiac disease (ie, sprue), prior gastrectomy or upper bowel removal, or any other gastrointestinal disorder or defect that would interfere with the absorption, distribution, metabolism, or excretion of the IP and/or predispose the subject to an increased risk of 
gastrointestinal toxicity.
5. Subject has an impaired ability to swallow oral medication.
6. Subject has persistent diarrhea or malabsorption â‰¥ National Cancer Institute Common 
Terminology Criteria for Adverse Events (NCI CTCAE) Grade 2, despi[INVESTIGATOR_72604].
                                               
* True abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject. (Periodic 
abstinence [eg, calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable 
methods of contraception).&(/*(1(3atat35235,(7$5<,1)250$7,21aceptieptive vei
the coursethe course
ast dose ofast dose o
eded.ded.
related related 
r protocol rprotocol r
ctfrofrom menroenr
tasis. In tasis. In susu
.  Primary.  Primary Nyy
nsidered brnsidered br
itthin 5 yearhin 5 year
sisitu carcintu carciniii
treatment treatment 
squamous quamous
 PSA <10PSA <[ADDRESS_78716]
6.6.SubjSubj
TT
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 38 CC-486-NPC-001 Final: [ADDRESS_78717] has significant active cardiac disease within the previous 6 months including 
unstable angina or angina requiring surgical or medical intervention, significant cardiac 
arrhythmia, or [LOCATION_001] Heart Association (NYHA) class [ADDRESS_78718] has a known or suspected hypersensitivity to azacitidine, mannitol, or any other 
ingredient used in the manufacture  of CC-486 (see the Azacitidine IB).
9. Subject has a known history or current diagnosis of human immunodeficiency virus 
(HIV) infection, regardless of treatment status.
10. Subject has any other concurrent severe and/or uncontrolled medical condition that 
would, in the Investigatorâ€™s judgment, c ontraindicate sub ject particip ation in the clinical 
study (eg, chronic pancreatitis, chronic active hepatitis, etc.).
11. Subject has had major surgery within [ADDRESS_78719] has received another investigational therapy within 28 days or 5 half lives of 
randomization/enro llment, whichever is shorter.
13. Subject has not recovered from the acute toxic effects of prior anticancer therapy, 
radiation, or major surge ry/significant trauma.
14. Subject has had radiotherapy â‰¤ 4 weeks or limited field radiation for palliation â‰¤ 2 weeks 
prior to starting IP, and/or from whom â‰¥ 30% of the bone marrow was irradiated.
15. Subject is pregnant or breast feeding.
16. Subject has any significant medical condition, laboratory a bnormality, or psychiatric 
illness that would prevent the subject from participating in the study.
17. Subject has any condition incl uding the presence of laboratory a bnormalities, which 
places the subject at unacceptable risk if he/she were to participate in the study.
18. Subject has any condition that confounds the ability to interpret data from the study.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21t t 
e clinical e clinical 
not recovernot reco
ays or [ADDRESS_78720], laboab
t from pat from pa rtrta
ding the preing the p
table risk ifable risk
that confothat confo
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 39 CC-486-NPC-001 Final: [ADDRESS_78721](s)
Celgene Corporation will supply CC-486 100-, 150-, and/or 200-mg tablets for oral 
administration.  All tablets will be packaged in blister packs. Each tablet is formulated using 
excipi[INVESTIGATOR_72605].  A list of 
excipi[INVESTIGATOR_72606].
All IP must be stored in an area free of environmental extremes and a secured area to prevent 
unauthorized access, as directed on the package label. A temperature log must be maintained.
8.2. Treatment Administration and Schedule
CC-486 will be administered at a dose of 300 mg orally daily (QD) for [ADDRESS_78722] 6 Asian-Pacific Island ethnicity subjects evaluable for safety will 
receive CC-486 at a dose of 200 mg orally daily for 14 of 21 days of Cycle 1; and if well-tolerated, and there are no safety concerns, (see Section 8.2.1 ) subsequent subjects of Asian-
Pacific Island ethnicity will be administered at the [ADDRESS_78723] IP with approximately 240 mL (8 ounces) of room temperature water.  
Investigational product may be taken on an empty stomach or with food (a light breakfast or 
meal of up to approximately 600 calories), except on PK sampling days.
8.2.1. Tolerability Determination in Asian-Pacific Island Ethnicity
The first 6 evaluable for safety subjects of Asian-Pacific island ethnicity receiving 200 mg daily 
will be assessed for tolerability and determination if dose can be increased to 300 mg daily in subsequent subjects.  If â‰¤ [ADDRESS_78724] of Asian-Pacific Island et hnicity experiences a dose-limiting 
toxicity (DLT), the initial 200 mg dose will be increased to the 300 mg dose in subsequent subjects. If â‰¥2 subjects of Asian-Pacific Island ethnicity experience a DLT, the dose may be 
decreased to 150 mg daily, at the discretion of the sponsor.
A DLT is defined as an IP-related AE(s) occurring in Cycle 1 (including predose assessments on 
Cycle 2 Day 1) that leads to permanent treatment discontinuation or meets one of the following 
criteria:
!Grade 4 neutropenia lasting > 10 days or accompanied by [CONTACT_411] (defined as >
38.5Â°C 
requiring hospi[INVESTIGATOR_059]);
!Grade 3 thrombocytopenia with clinically significant bleeding; and,
!Any Grade â‰¥ 3 non-hematologic toxicity with the following exceptions:
âˆ€Grade 3 emesis that responds to optimal antiemetic therapy within 72 hours;
âˆ€Grade 3 diarrhea that responds to optimal medical management within 72 hours;
âˆ€Grade [ADDRESS_78725] who had Grade 2 fatigue at study entry and that 
recovers to baseline grade or less within 72 hours;&(/*(1([ZIP_CODE],(7$5<,1)250$7,21vent en
ntainedtained .
ayays ofs ofa 212f
ble ble fofor safers a f e
ycle 1ycle 1 ; and; an
equentuent ssubjubj
dose for 14se for 1
nces) of roonces) of roo
mmach or wiach or wi ttii
n PK sampn PK sam
an-n-PacificPacific
f AsianAsian --PacPac
erminatrminat ioionn
of Asianf Asian --Pa
g dose will bdose wil
ann--Pacific IPacific 
at the diat the di scrsc
IPIP-related related
eads to pereads to pe
rade 4 neutrade 4 neut
requirequi ririiiing hng 
!!Graderade
!!AA
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 40 CC-486-NPC-001 Final: 11 July 2014âˆ€Grade 3 or 4 laboratory abnormalities that are not accompanied by [CONTACT_27651].
An event that starts in Cycle 1 (including Cycle 2 Day 1 predose assessments) that becomes a 
DLT due to its duration will be considered a DLT.
8.2.2. Dose Adjustment Guidelines
A maximum of [ADDRESS_78726] including, but not limited to, Grade 3 or 4 hematologic or non-
hematologic toxicity. Subjects should be discontinued after the 3
rdepi[INVESTIGATOR_1865].
Please refer to Table 4 for the Dose Adjustment Guidelines due to unacceptable toxicity.
Table 4: Dose Adjustments and Dose Delays for Toxicity
Toxicity Recommendation
Grade 2 hematologic toxicity causing delay to 
the planned start of a Cycle
Absolute Neutrophil Count (ANC) < 1.5 x 
109/L
Platelets < 75 x 109/LHold CC-486 until ANC & Platelets â‰¤ Grade 1
Delay â‰¤7 days, resume CC-486 at same dose
Delay 8 â€“ 14 days, reduce CC-486 by 50 mg
Delay > 14 days, permanently discontinue from study
Grade 3* neutropenia or thrombocytopenia 
causing delay to the planned start of a Cycle 
ANC 0.5-0.99 x 109/L
Platelets 25-49 x 109/LHold CC-486 until ANC & Platelets recover to < Grade 1 
(ANC â‰¥1.5 x 109/L, Platelets â‰¥ 75 x 109/L)
Recovery in â‰¤ 7 days, resume CC-486 at same dose
Recovery in 8â€“14 days, reduce CC-486 by 50 mg
No recovery by 14 days, pe rmanently discontinue from 
study
Grade 4* neutropenia or thrombocytopenia 
causing delay to the planned start of a Cycle
ANC < 0.5 x 109/L
Platelets < 25 x 109/L
For ANC < 0.5 x 109/L
The initiation of G-CSF is left at the 
Investigatorâ€™s discretion. If initiated administer G-CSF per institutional practice or package insert and continue until ANC recovers to â‰¥ 2.0 
x 10
9/LHold CC-486 until ANC & Platelets recover to < Grade 1
(ANCâ‰¥ 1.5 x 109/L, Platelets â‰¥75 x 109/L)
Recovery in â‰¤ 7 days, reduce CC-486 by 50 mg
No recovery by 7 days, permanently discontinue from study
&(/*(1penia or thromenia or throm
to the planneo the planne
x1 0099/L/L
s < 25 s < 25 x 101099/
ANC < 0.5 xNC < 0.5 x
he initiationhe initiation
nvestigatovestiga
SFSF(1([ZIP_CODE],(7$5<,1)250$7,21ext ex
se reductione reductio
table toxicitable toxic
defined as aefined as 
medical riskdical risk
or 4 hemaor 4 he
the 3he 3rdrepi[INVESTIGATOR_72607] s for Toxicfor Tox
mendationmendation(7ld CCld CC -486 u486 u
Delay Delay â‰¤7â‰¤dd
Delay 8 Dela
DelayDela5,(
2openia openia 
of a Cycle of a Cycle [ZIP_CODE]
(1
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 41 CC-486-NPC-001 Final: 11 July 2014Table 4: Dose Adjustments and Dose Delays for Toxicity (Continued)
Toxicity Recommendation
Grade 3 or 4 non-hematologic toxicity or other 
Investigator defined unacceptable toxicityHold CC-486 until recovery to baseline
Recovery in â‰¤ 7 days, resume CC-486 at same dose
Recovery in 8-14 days, reduce CC-486 by 50 mg
No recovery by 14 days, withdraw from study
In case of recurrence of the Grade 3 or 4 toxicity, hold CC-
486 until recovery to baseline. Recovery in â‰¤ 7 days, reduce 
CC-486 by 50 mg. No recovery by 7 days, withdraw from 
study
ANC = absolute neutrophil count; ASCO = American Society of Clinical Oncology; ESMO = European Society for Medical 
Oncology; G-CSF = granulocyte colony stimulating factor.
Note: The initiation of G-CSF is left at the Investigatorâ€™s discretion.
Note: Granulocyte colony s timulating factor (G-CSF) should only be utilized in accordance to ASCO or ESMO 
recommendations.
Note: If Grade 3 or 4 neutropenia associated with fever or Grade â‰¥ 3 thrombocytopenia with clinically significant bleeding 
occurs at any time, the dose adjustment guidelines for Grade 4 hematological toxicity should be enacted.
Note: If neutropenia is associated with fever and severe diarrhea, subject should be managed appropriately according to the local 
practice. In case of recurrence of the diarrhea with neutropenia and fever, the continuation of the subject in  the study s hould be 
discussed on a case-by-case basis with the sponsor â€™s study monitor.
8.2.3. Missing Doses
All efforts should be made to administer IP on all of the scheduled days of each 21-day treatment 
cycle. Any missed doses during that period should not be added after the last scheduled day of 
administration, but should be returned by [CONTACT_72639].
8.2.4. Overdose
Overdose, as defined for this protocol, refers to CC-[ADDRESS_78727], regardless of any associated adverse events or sequelae.
!PO (oral) - any amount over the protocol-specified dose
On a schedule or frequency basis, an overdose is defined as anything more frequent than the protocol required schedule or frequency.
Complete data about drug administration, including any overdose, regardless of whether the 
overdose was accidental or intentional, should be reported in the case report form (CRF).
8.3. Method of Treatment Assignment
Subjects who enter screening will be assigned the next available subject number. All eligible 
subjects will receive CC-486.
All IP will be managed by [CONTACT_72640] a central subject number assignment and 
accountability tool only.
8.4. Packaging and Labeling
The labels for IP will include s ponsor name, address and telephone number, the protocol number, 
IP name, dosage form and strength (where applicable), amount of IP per container, lot number, &(/*(1([ZIP_CODE],(7$5<,1)250$7,210$0$0$Medical dical 
MO O
significant blsignificant 
nacted.nacted.
ropriately accopriately
f the subject ithe subject 
heduled dayeduled d
be addedadded af
for IP accofor IP ac
rs to CCs to CC --4848
ned as ned as anyan
regardless regardles
unt over theunt over the
bbasis, an oasis, an
le or frequele or fre
drug admindrug adm
dental or indental or in
Method oMethod o
s who enters who ente
ects will reccts will re
All IP will bAll IP will b
accountaccounta
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 42 CC-486-NPC-001 Final: 11 July 2014expi[INVESTIGATOR_5695] (where applicable), medication identi fication/kit number, dosing instructions, storage 
conditions, and required caution statements and/or regulatory statements as applicable. 
Additional information may be included on the label as applicable per local regulations.
8.5. Investigational Product Accountability and Disposal
Celgene (or designee) will review with the Investigator and relevant site personnel the process 
for Investigational Product return, disposal, and/or destruction including responsibilities for the 
site vs. Celgene (or designee).
8.6. Investigational Product Compliance
Accurate recording of all IP administered will be made in the appropriate section of the subjectâ€™s 
case report form (CRF) and source documents. The Investigator or designee is accountable for 
the compliance of all study-specific IP either administered or in their custody during the course 
of the study.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21hhe subjectâ€™e subject
ountableountable fof
during the curing the
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 43 CC-486-NPC-001 Final: 11 July [ZIP_CODE]. CONCOMITANT MEDICATIONS AND PROCEDURES
In general, the use of any c oncomitant medication/therapi[INVESTIGATOR_72608].
All concomitant treatments, including blood and blood products, must be reported on the CRF.
9.1. Permitted Concomitant Medications and Procedures
Subjects may be administered supportive and palliative care (eg, pain control) as clinically 
indicated throughout the study.
The use of myeloid growth factors (granulocyte colony stimulating factor [G-CSF] and 
granulocyte macrophage colony-stimulating factor [GM-CSF]) may be given per Investigatorâ€™s 
discretion and according to American Society of Clinical Oncology (ASCO) and European 
Society for Medical Oncology (ESMO) guidelines only for the tr eatment of neutropenic 
infections.
Antiemetics are not required during the study; how ever, at the Inve stigatorâ€™s discretion, subjects 
may receive prophylactic antiemetics approximately [ADDRESS_78728] sign of diarrhea. Pre-
medication with antidiarrheal medication for subsequent doses of CC-486 may be appropriate at 
the Investigatorâ€™s discretion.
9.2. Prohibited Concomitant Medications and Procedures
The following concomitant medications are specifically prohibited during the course of the 
study:
Cytotoxic, chemotherapeutic, targeted, or investigational agents/therapi[INVESTIGATOR_72609].
Vidaza (azacitidine), decitabine, or other demethylating agents.
9.3. Required Concomitant Medications and Procedures
Not applicable.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21and nd 
Investinvesti gatgat
nd Ed Europeurope
f neutropenf neutropen
igatorgator â€™s diâ€™s di
priior to eacor to eac
ddat the firat the fi
doses of oses of CCCC
ationsations ana
pecifically pecifically
d, or , or investinvest ii
e, or other d, or other 
ConcomitaConcom
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 44 CC-486-NPC-001 Final: [ADDRESS_78729] v1.1.
10.2. Study Population Definitions
The following study population w ill be used for this study:
!Safety Population â€“ All subjects w ho received at least one dose of IP.
!Efficacy Evaluable Population â€“ All subjects who meet all eligibility criteria, and 
EITHER
1. Received at least two cycles of IP at any dose intensity and discontinued 
treatment for progressive disease, OR
2. Received at least four cycles of IP at any dos e intensity and have baseline and at 
least two post-screening tumor assessments.
Subjects not eligible for the Efficacy Evaluable population will be replaced at the discretion of 
the sponsor.
!Pharmacokinetic Population â€“ All subjects who have evaluable pharmacokinetic data from at least one dose of IP.
Subjects receiving the [ADDRESS_78730] imation is based on having s ufficient sample in the Efficacy Evaluable
population to show that the ORR is higher than 20% or median PFS is > 5 months. Simonâ€™s 
optimal two-stage design will be used ( Simon, 1989). The null hypothesis that the true ORR is at
least 20% or median PFS is at least [ADDRESS_78731] stage, 17 subjects will be accrued. If there are 4 or fewer responders in these 17 subjects, enrollment will be stopped. Otherwise, 34 additional subjects will be accrued for a total of 51subjects. Subjects who progress to the end of Cycle 1 are not evaluable for efficacy and will be 
replaced. This Phase 2 study will be considered positive if more than 14 responders are observed 
in 51 subjects or the hypothesis of median PFS equal to 5 months is rejected. This design yields a 
marginal one-sided type I error rate of 5% and power of 85% when the true ORR is 40%. After 
the second stage (n = 51), the power for showing median PFS is > 5 months is 80% (60%) when 
the true median PFS is about 8(7) months.&(/*(1([ZIP_CODE],(7$5<,1)250$7,211.1.1
y y cricriteriateriaii
tyand discand disc
e intensitintensit y ay
s.s.
atatioion will bwill b
ects who haects who h
l be beefficaceffica
d Power Cd Power C
fficacy evalcacy eva
imatmatioion n is is 
ow that theow that the
tage designage desig
or medianr median P
ge,ge177subjsubj
llment willllment wil
ubjects. ubjects. SubSub
replepaced. ced. 
5151ss
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 45 CC-486-NPC-001 Final: 11 July 201410.4. Background and Demographic Characteristics
Subjectsâ€™ age, height, weight, and baseline characteristics will be summarized using descriptive 
statistics, while gender, race and other categorical variables will be provided using frequency 
tabulations.  Medical history data will be summarized using frequency tabulations by [CONTACT_53428].
10.5. Subject Disposition
Subject disposition (analysis population allocat ion, entered, discontinued, along with primary 
reason for discontinuation) will be summarized using frequency and percent for both treatment and follow-up phases.  A summary of subjects enrolled by [CONTACT_27707]. Protocol deviations will be summarized using frequency tabulations.
10.6. Efficacy Analysis
Efficacy analyses will be perfor med on the Efficacy Evaluable population.
The hypothesis testing for the ORR will be based on the exact binomial distribution. The point 
estimate and two-sided 90% confidence interval (CI) of ORR will be provided. In addition, if 
Stage 2 is conducted, the Kaplan-Meier procedure will be used to estimate the median PFS and two-sided 90% CI. The hypothesis testing for the PFS will be based on the exponential 
distribution.
Subjects who die, regardless of the cause of death, will be considered to have had an event.  
Subjects who withdraw consent for the study will be considered censored at the time of 
withdrawal.  Subjects who are still alive at the time of the clinical data cut-off date will be 
censored.  All subjects who were lost to follow-up prior to the clinical data cut-off date will also be considered censored at the time of last contact.
The Kaplan-Meier procedure will be used to estimate proportions of event-free intervals for OS.  
Median OS and two-sided 90% CI will be provided.
10.7. Safety Analysis
The safety population will be included in the safety analyses.
Safety and tolerability will be monitored through continuous reporting of adverse events and serious adverse events, labora tory abnormalities, and incide nce of subjects experiencing dose 
modifications, dose interruptions, and/or premature discontinuation of IP. Data from all subjects 
who receive one or more doses of IP w ill be included in the safety analyses. Adverse events, 
physical examinations (including vital sign measurements), clinical laboratory information, and concomitant medications/procedures will be tabulated and summarized.
Adverse events will be analyzed in terms of TEAE defined to be any event that begins or 
worsens in grade after the start of IP through [ADDRESS_78732] dose of IP. Adverse events will be summarized by [CONTACT_926]/grade based on the CTCAE v4.[ADDRESS_78733] se verity. All AEs, as well as TEAEs, will be 
summarized by [CONTACT_6657]. Adverse events leading to death or to 
discontinuation from treatment, events classified as CTCAE Grade 3 or Grade 4, IP related &(/*(1([ZIP_CODE],(7$5<,1)250$7,21yy
ment ment 
ol 
al distributl distribut i
be prbe pr oviovidedd
o estimate o estimate 
based on tbased on
l be considl be consid
e consideree consider
me of the cme of the c
w-wup priup pri or or 
ontact.ntact.
sed to estimsed to estim
will be provill be pro
l be include inc
y willy will bblle me 
ents, laboraents, labora
dose interrudose interru
one or morone or mo
examinataminat ioio
mitant mediitant medi
verse evenerse even
worsens inworsens in
will be will be
t
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 46 CC-486-NPC-001 Final: 11 July 2014events, and serious adverse events will be summarized separately. Adverse events will be coded 
according to the Medical Dictionary for Regulatory Activities (MedDRA). Adverse events of 
special interest of CC- 486 identified in previous trials will be summarized in a similar manner.
10.8. Interim Analysis
Interim analysis will be performed according to Simonâ€™s optimal design based on the population 
evaluable for efficacy as described in Section 10.2.
10.9. Assessment of Pharmacokinetics
Pharmacokinetic measures are incorporated into th e study to assess the extent of exposure, and to
explore the relationship between CC-486 and PD effects. Blood samples for PK will be collected from a subset of subjects at selected visits. As appropriate, PK parameters, but not limited to the 
following, will be determined from plasma concentration versus time profile data:
!Area under the plasma concentration time-curve (AUC);
!Peak (maximum) plasma concentration (C
max);
!Terminal half-life (t 1/2);
!Time to maximum plasma concentration (T max);
!Clearance (apparent, CL/F); and,
!Volume of distribution (apparent, V z/F).
Descriptive statistics (N, mean, standard deviation, coefficient of variation [CV%], geometric 
mean, geometric CV%, median, min, and max) will be provided for all data. Results will be presented in tabular and graphic forms as appropriate.
Sample collection kits and detailed instructions for PK sample co llection, processing, storage, 
shippi[INVESTIGATOR_007], and handling will be provided to the Investigator sites upon study initiation.
Plasma azacitidine will be measured using validated liquid chromatography-mass spectrometry 
methods (LC-MS/MS).
10.10. Other Topi[INVESTIGATOR_72610] e [ADDRESS_78734] and Interim Efficacy results will be disc ussed with the regional Principal Investigators 
(PIs) regularly. The interval of these reviews will be defined with the PIs at th e Kick-off 
Meeting.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21ure, and toure, and t
be collectebe collecte
t limlimitited toed to
ata:ta:
nn, coefficie, coeffici
x) will be prx) will be p
ppropriate.propriate
tructions fouctions fo
ided to the ded to th
ured using ured using
pi[INVESTIGATOR_72611] C
erim Efficaerim Effica
ly. The intey. The inte
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 47 CC-486-NPC-001 Final: 11 July 201411. ADVERSE EVENTS
11.1. Monitoring, Recording and Reporting of Adverse Events
An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may 
appear or worsen in a subject during the course of a study. It may be a new intercurrent illness, a 
worsening concomitant illness, an  injury, or any concomitant impairment of the subjectâ€™s health, 
including laboratory test values (as specified by [CONTACT_14540] 11.3), regardless of 
etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a pre-existing condition) should be  considered an AE.  A diagnosis or syndrome 
should be recorded on the AE page of the CRF rather than the individual signs or symptoms of 
the diagnosis or syndrome.
Abuse, withdrawal, sensitivity or toxicity to an investigational product should be reported as an 
AE. Overdose, accidental or intentional, whether or not it is associated with an AE should be reported on the overdose CRF. (See Section 8.2.4 for the definition of overdose.) Any sequela 
of an accidental or intentional overdose of an investigational product should be reported as an AE on the AE CRF. If the sequela of an overdose is an SAE, then the sequela must be reported on an SAE report form and on the AE CRF. The overdose resulting in the SAE should be 
identified as the cause of the event on the SAE report form and CRF but should not be reported 
as an SAE itself.
All subjects will be monitored for AEs during the study.  Assessments may include monitoring 
of any or all of the following parameters:  the subjectâ€™s clinical symptoms, laboratory, 
pathological, radiological or surgical findings, phys ical examination findings, or findings from 
other tests and/or procedures.
All AEs will be recorded by [CONTACT_72641] i nformed consent 
until [ADDRESS_78735] dose of IP and those SAEs made known to the Investigator at any time 
thereafter that are suspected of being related to IP. AEs and serious adverse events (SAEs) will 
be recorded on the AE page of the CRF and in the subjectâ€™s source documents.  All SAEs must 
be reported to Celgene Drug Safety within 24 hours of the Investigatorâ€™s knowledge of the event 
by [CONTACT_6972], or other appropriate method, using t he SAE Report Form, or approved equivalent 
form.
11.2. Evaluation of Adverse Events
A qualified Investigator will evaluate all adverse events as to:
11.2.1. Seriousness
A serious adverse event (SAE) is any AE occurring at any dose that:
!Results in death;
!Is life-threatening (ie, in the opi[INVESTIGATOR_689], the subject is at immediate 
risk of death from the AE);&(/*(1([ZIP_CODE],(7$5<,1)250$7,21rome me 
mptoms of mptoms of 
be reportebe reporte
th an AE shh an AE sh
overdose.)erdose
should be should be
n the sequelthe seque
ltting ing in the
and CRF bund CRF b
dydy.  Assess.  Assess
ectâ€™s clinicectâ€™s clinic
physihysicalcal ex ell
gatoratorfrom from t
and those Sand tho
ng related tng related 
the CRF anhe CRF an
SafetSafet y y wiwti
ropriropri ate mate
uation ofuation of
nvestnvest igatorigator
SeriouSeriou
erious erious advadv
!!
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 48 CC-486-NPC-001 Final: 11 July 2014!Requires inpatient hospi[INVESTIGATOR_27588] 
(hospi[INVESTIGATOR_19357], regardless of length of stay);
!Results in persistent or significant disability/incapacity (a substantial disruption of the 
subjectâ€™s ability to conduct normal life functions);
!Is a congenital anomaly/birth defect;
!Constitutes an important medical event.
Important medical events are defined as thos e occurrences that may not be immediately life 
threatening or result in death, hospi[INVESTIGATOR_059], or disability, but may jeopardize the subject or require medical or surgical intervention to prevent one of the other outcomes listed above.  
Medical and scientific judgment should be exercised in deciding whether such an AE should be considered serious.
Events not considered to be SAEs are hospi[INVESTIGATOR_5315]:
!A standard procedure for protocol therapy administration.  However, hospi[INVESTIGATOR_72612] a complication of therapy administration will be 
reported as an SAE.
!Routine treatment or monitoring of the studied indication not asso ciated with any 
deterioration in condition.
!The administration of blood or platelet transfusion as routine treatment of studied indication.  However, hospi[INVESTIGATOR_27589] a complication 
of such transfusion remains a reportable SAE.
!A procedure for protocol/disease-related investigations (eg, surgery, scans, 
endoscopy, sampling for laboratory tests, bone marrow sampling).  However, hospi[INVESTIGATOR_27590] a complication of such procedures 
remains a reportable SAE.
!Hospi[INVESTIGATOR_27591], practical, or social reasons, in absence of an AE.
!A procedure that is planned (ie, planned prior to starting of treatment on study); must 
be documented in the source document and the CRF.  Hospi[INVESTIGATOR_72613] a complication remains a reportable SAE.
!An elective treatment of or an elective procedure for a pre-existing condition unrelated to the studied indication.
!Emergency outpatient treatment or observation that does not result in admission, unless fulfilling other seriousness criteria above.
If an AE is considered serious, both the AE page/screen of the CRF and the SAE Report Form must be completed.
For each SAE, the Investigator will provide i nformation on severity, start and stop dates, 
relationship to IP, action taken regarding IP, and outcome.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21or 
ve.  ve.  
E should beE should be
wever, hoswever, ho
administratdministra
atiationonnot a
fusiofusio n as ron as r
rolonged horolonged
e SAE.e SAE.
elelated inveated inve
toryorytests, btests, yy
hospi[INVESTIGATOR_72614] 
e of an AE.e of an AE
hat is plannhat is pl
nted in the nted in the 
zatiation fon for or fff
lectlective treive tre
nrelated tonrelated to
EmergeEmerg
unlesunl
f an AE if an AE i scs
must be cmust be c
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 49 CC-486-NPC-001 Final: 11 July 201411.2.2. Severity / Intensity
For both AEs and SAEs, the Investigator must assess the severity / intensity of the event.
The severity / intensity of AEs will be gra ded based upon the subjectâ€™s symptoms according to 
the current active minor version of the CTCAE, Version 4.0;
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40
AEs that are not defined in the CTCAE should be  evaluated for severity / intensity according to 
the following scale:
!Grade 1 = Mild â€“ transient or mild discomfort; no limitation in activity; no medical 
intervention/therapy required
!Grade 2 = Moderate â€“ mild to moderate limitation in activity, some assistance may be 
needed; no or minimal medical intervention/therapy required
!Grade 3 = Severe â€“ marked limitation in activity, some assistance usually required; medical intervention/therapy required, hospi[INVESTIGATOR_27594]
!Grade 4 = Life threatening â€“ extreme limita tion in activity, significant assistance 
required; significant medical intervention/therapy required, hospi[INVESTIGATOR_27595]
!Grade 5 = Death - the event results in death
The term â€œsevereâ€ is often used to describe the intensity of a specific event (as in mild, moderate 
or severe myocardial infarction); the event itself, however, may be of relatively minor medical significance (such as severe headache).  This criterion is notthe same as â€œseriousâ€ which is 
based on subject/event outcome or action criteria associated with events that pose a threat to a 
subjectâ€™s life or functioning.
Seriousness, not severity, serves as a gui de for defining regulatory obligations.
11.2.3. Causality
The Investigator must determine the relationship between the administration of IP and the 
occurrence of an AE/SAE as Not Suspected or Suspected as defined below:
Not suspected: Means a causal relationship of the adverse event to IP
administration is unlikely or remote , or other medications, 
therapeutic interventions, or underlying conditions provide a 
sufficient explanation for the observed event.
Suspected: Means there is a reasonable possibility that the administration 
of IP caused the adverse event.  â€˜Reasonable possibilityâ€™ means there is evidence to suggest a causal relationship between the IP 
and the adverse event.
Causality s hould be a ssessed and provided for every AE/SAE based on currently available 
information.  Causality is to be reassessed and provided as additional information becomes available.&(/*(1([ZIP_CODE],(7$5<,1)250$7,21calal
stance maytance may
e usually re usually r
bleble
y, significan significan
red, hospi[INVESTIGATOR_5697], hospi [INVESTIGATOR_62300]
y of a spey of a spe cic
wever, maywever, m
erioerion n is nono
ria associa associ ata
uiide fde for defor defff
ne the relane the rela
as Not Susps Not Sus
MeanMea
admadm
Suspected:Suspected:
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 50 CC-486-NPC-001 Final: [ADDRESS_78736] of the start and stop dates of the 
event.
11.2.5. Action Taken
The Investigator will report the action taken with IP as a result of an AE or SAE, as applicable 
(eg, discontinuation, interruption, or reduction of IP, as appropriate) and report if concomitant and/or additional treatments were given for the event.
11.2.6. Outcome
The Investigator will report the outcome of the event for both AEs and SAEs.
All SAEs that have not resolved upon discontinuation of the subjectâ€™s participation in the study 
must be followed until recovered, recovered with sequelae, not recovered or death (due to the 
SAE).
11.3. Abnormal Laboratory Values
An abnormal laboratory value is considered to be an AE if the abnormality:
!results in discontinuation from the study;
!requires treatment, modification/ interrup tion of IP dose, or any other therapeutic 
intervention; or
!is judged to be of significant clinical importance.
Regardless of severity grade, only laboratory abnormalities that fulfill a seriousness criterion 
need to be documented as a serious adverse event.
If a laboratory abnormality is one component of a diagnosis or syndrome, then only the diagnosis 
or syndrome should be recorded on the AE page/screen of the CRF.  If the abnormality was not a 
part of a diagnosis or syndrome, then the labor atory abnormality should be recorded as the AE. If 
possible, the laboratory abnormality should be r ecorded as a medical term and not simply as an 
abnormal laboratory result (eg, record throm bocytopenia rather than decreased platelets).
11.4. Pregnancy
All pregnancies or suspected pregnancies occurring in either a female subject or partner of a 
male subject are immediately reportable events .
11.4.1. Females of Childbearing Potential:
Pregnancies and suspected pregnancies (including a positive pregnancy test regardless of age or 
disease state) of a female subject occurring while th e subject is on IP, or within [ADDRESS_78737]â€™s last dose of CC-486, are considered immed iately reportable events.  IP is to be icable able 
coomitmitant ant 
AEs.AEs.
partiparticipatcipat
covered or dovered or
AE AE ifththe a
udydy;;
interruptioninterruptio
ant clinical ant clini
yyllyyaboratoryaborato
rious adverous adve
yiys one cos one
recorded orecorded o
r syndrosyndro mem
ratoryratory abnoabnoyy
ratoryatory resuresyy
PregnaPregn
pregnanciespregnancie
male subjectmale subject
[IP_ADDRESS].4.1.
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 51 CC-486-NPC-001 Final: [ADDRESS_78738] 
notify Celgene Drug Safety immediately about the outco me of the pregnancy (e ither normal or 
abnormal outcome) using the Pregnancy Follow-up Report Form, or approved equivalent form.If the outcome of the pregnancy was abnormal (e g, spontaneous abortion), the Investigator
should report the abnormal outcome as an AE. If the abnormal outcome meets any of the serious 
criteria, it must be reported as an SAE to Celgene Drug Safety by [CONTACT_6972], or other appropriate 
method, within 24 hours of the Investigatorâ€™s know ledge of the event using the SAE Report 
Form, or approved equivalent form.
All neonatal deaths that occur within [ADDRESS_78739] to 
causality, as SAEs.  In addition, any infant d eath after 28 days that th e Investigator suspects is 
related to the in utero exposure to the IP should also be reported to Celgene Drug Safety by 
[CONTACT_6972], or other appropri ate method, within 24 hours of the Investigatorâ€™s knowledge of the 
event using the SAE Report Form, or approved equivalent form.
11.4.2. Male Subjects
If a female partner of a male subject taking CC-[ADDRESS_78740] dose of CC-486. The ICF will address any country-specific requirements, as needed.
11.5. Reporting of Serious Adverse Events
Any AE that meets any criterion for an SAE requires the completion of an SAE Report Form in addition to being recorded on the AE page/screen of the CRF.  All SAEs must be reported to 
Celgene Drug Safety within 24 hours of the Investigatorâ€™s knowledge of the event by [CONTACT_6972], 
or other appropriate method, using the SAE Report Form, or approved equivalent form.  This instruction pertains to initial SAE report s as well as any follow-up reports.
The Investigator is required to ensure that the data on these forms is accurate and consistent.  This requirement applies to all SAEs (regardless of relationship to CC-486) that occur during the 
study (from the time the subject signs informed  consent until [ADDRESS_78741] (IP), and any SAE made known to the Investigator at anyt ime thereafter 
that are suspected of being related to IP.  SAEs occurring prior to treatment (after signing the ICF) will be captured.
The SAE report should provide a detailed description of the SAE and include a concise summary 
of hospi[INVESTIGATOR_27598] .  If a subject died and an autopsy has been 
performed, copi[INVESTIGATOR_27599] d eath certificate are to be sent to Celgene Drug &(/*(1([ZIP_CODE],(7$5<,1)250$7,21r 
formform .
gatorator
oof f ththe serie seri
ther appropther approp
e SAE Repe SAE Rep
ed, withoutd, withou
he InvestInves igi
to Celgene Celgene
InvestigatoInvestig
formorm..
866becobec meme
pregnant fpregnant f
female parfemale par
hcare profhcare prof
the course the course 
ress any couss any co
Serious ASerious A
criterion forriterion 
rded on therded on t
ty ywiwiththiiin 2in 2
riate methoiate metho
ertains to inertains to in
stigatorgator is ris r
equiequiremenremeniii
dyy(f(fyyromromfff  ththmm
investigatnvestigat ioio
thhat are at are
F)
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 52 CC-486-NPC-001 Final: [ADDRESS_78742]/Ethics Committee (IRB/EC) of the SAE and providing them with all relevant initial and follow-up information about the event. The Investigator must keep copi[INVESTIGATOR_72615]/EC.
11.5.1. Safety Queries
Queries pertaining to SAEs will be communicated from Celgene Drug Safety to the site via 
facsimile or electronic mail.  The response time is expected to be no more than five (5) business 
days.  Urgent queries (eg, missing causality assessment) may be handled by [CONTACT_648].
11.6. Expedited Reporting of Adverse Events
For the purpose of regulatory reporting, Celgene Drug Safety will determine the expectedness of events suspected of being related to CC-486 based on the Azacitidine Investigatorâ€™s Brochure.
In the [LOCATION_002], all suspected unexpected serious adverse reactions (S[LOCATION_003]Rs) will be 
reported in an expedited manner in accordance with 21 CFR 312.32.
For countries within the European Economic Area (EEA), Celgene or its authorized 
representative will report in an expedited manner to Regulatory Authorities and Ethics 
Committees concerned, S[LOCATION_003]Rs in accordance with Directive 2001/20/EC and the Detailed Guidance on collection, verification and presentation of adverse reaction reports arising from clinical trials on investigational products for human use (ENTR/CT3) and also in accordance 
with country-specific requirements.
Events of disease progression for the disease unde r study (including deaths due to disease 
progression for indications that are considered to be fatal) will be assessed as expected adverse 
events and will not be reported as exped ited safety reports to regulatory authorities.
Celgene or its authorized re presentative shall notify the Investigator of the following information
!Any AE suspected of being related to the use of IP in this study or in other studies
that is both serious and unexpected (ie, S[LOCATION_003]R);
!Any finding from tests in laboratory animals that suggests a significant risk for human subjects including reports of mutagenicity, teratogenicity, or carcinogenicity; and,
Where required by [CONTACT_19666], the Investigator shall notify his/her IRB/EC promptly of 
these new serious and unexpected AE(s) or significant risks to subjects.
The Investigator must keep copi[INVESTIGATOR_27601]/EC.  (See Section 15.[ADDRESS_78743] retention 
information).
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21business siness 
e the expece the expe
vestestigatorigat â€™s
ons (S[LOCATION_003]ns (S[LOCATION_003]
32.2.
elgene or itelgene or 
latoryatory AuthAuthyy
irectirective 20ive 20
n of adversen of adve
an use (ENan use (EN
ase under stse under st
sidered to bidered to
pedited safpedited s
entative entative shasha
ed of beinged of bein
rious and urious an
ng frong fro m m tet
subjectsubject s ins in
,
uired by[CONTACT_72642]
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 53 CC-486-NPC-001 Final: [ADDRESS_78744] Information:
!For Celgene Drug Safety c ontact information, please refe r to the Serious Adverse 
Event Report Form Completion Guidelines  or to the Pregnancy Report Form 
Completion Guidelines.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 54 CC-486-NPC-001 Final: [ADDRESS_78745] and/or from the study:
!Adverse Event
!Progressive Disease
!Symptomatic deterioration (global deterioration of h ealth status)
!Physician decision
!Withdrawal by [CONTACT_1130]
!Death
!Lost to follow-up
!Protocol violation
!Other (to be specified on CRF)
The reason for discontinuation should be recorded in the CRF and in the source documents.
The decision to discontinue a subject remains the responsibility of the treating physician, which 
will not be delayed or refused by [CONTACT_456]. However, prior to discontinuing a subject, the 
Investigator may contact [CONTACT_72643].
12.2. Study Discontinuation
The following events are considered sufficient reasons for discontinuing a subject from the study follow-up periods:
!Withdrawal of consent
!Death
!Lost to follow-up
!Protocol violation
!Other
The reason for discontinuation should be recorded in the CRF and in the source documents.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21CRF and iCRF and
sponsibilitsponsibili y
wever, priowever, pri
and forwarand forwar
nn
red sufficiered suffic
consentonsen
followfollow -up-up
otocolocol vivillolol
OtherOther
eason for deason for
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 55 CC-486-NPC-001 Final: [ADDRESS_78746] the responsible Clinical Research
Physician/Medical Monitor or designee by [CONTACT_27722](s) listed on the Emergency 
Contact [CONTACT_27723] (after title page).
In the unlikely event that the Clinical Research Physician/Medical Monitor or designee cannot be 
reached, please contact [CONTACT_27724] (after title page). This global 
Emergency Call Center is available 24 hours a day and 7 days a week. The representatives are 
responsible for obtaining your call-back information and contact[CONTACT_27725]/Contract 
Research Organization Medical Monitor, who will then contact [CONTACT_27726].
Note: The back-up [ADDRESS_78747] call center should only be used if you are 
not able to reach the Clinical Research Physician(s) or Medical Monitor or designee for 
emergency calls.
13.2. Emergency Identification of Investigational Products
This is an open-label study; therefore, IP will be identified on the package labeling.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21ot be ot 
ed on d on 
ntatives are ntatives are
Celgene/CCelgene/C oo
nlynlybby[CONTACT_72644]
d on the pad on the pa
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 56 CC-486-NPC-001 Final: [ADDRESS_78748], evaluation, and 
documentation of this study are designed to ens ure that Celgene, its authorized representative,
and Investigator abide by [CONTACT_23663] (GCP), as described in International Conference on Harmonisation (ICH) Guideline E6 and in accordance with the general ethical principles outlined in the Declaration of Helsi nki. The study will receive approval from an 
IRB/EC prior to commencement. The Investigato r will conduct all aspects of this study in 
accordance with applicable national, state, and local laws of the pertinent regulatory authorities.
14.2. Investigator Responsibilities
Investigator responsibilities are set out in the ICH Guideline for Good Clinical Practice and in the local regulations.  Celgene staff or an authorized representative will evaluate and approve all Investigators who in turn will select their staff.
The Investigator should ensure that all persons assi sting with the study are adequately informed 
about the protocol, amendments, study treatments, as well as study-related duties and functions. 
The Investigator should maintain a list of Sub-Investigators and other appropriately qualified 
persons to whom he or she has d elegated significant study-related duties.
The Investigator is responsible for keepi[INVESTIGATOR_007] a record of all subjects who sign an informed consent 
document and are screened for entry into the study.  Subjects who fail screening must have the 
reason(s) recorded in the subjectâ€™s source documents.
The Investigator, or a designated member of the Investigatorâ€™s staff, must be available during 
monitoring visits to review data, resolve queries and allow direct access to subject records (eg, 
medical records, office charts, hospi[INVESTIGATOR_1332], and study-related charts) for source data 
verification.  The Investigator must ensure timely  and accurate completion of CRFs and queries.
14.3. Subject Information and Informed Consent
The Investigator must obtain informed consent of a subject and/or a subjectâ€™s legal representative 
prior to any study related procedures.
Documentation that informed consen t occurred prior to the study subjectâ€™s entry into the study 
and of the informed consent process should be recorded in the study subjectâ€™s source documents 
including the date.  The original informed consent document signed and dated by [CONTACT_72645]â€™s entry into the 
study, must be maintained in the Investigatorâ€™s study files and a copy given to the study subject.  
In addition, if a protocol is amended and it impacts on the content of the informed consent, the 
informed consent document must be revised.  Study  subjects participating in the study when the 
amended protocol is implemented must be re-conse nted with the revised version of the informed 
consent document.  The revised informed consent document signed and dated by [CONTACT_72646]â€™s study files and a copy given to the study subject.&(/*(1([ZIP_CODE],(7$5<,1)250$7,21in 
authoriauthori titiiieses
ical Practicical Practic
evaluate anvaluate
studyudare are
studystudy -relaterel
s and other and othe
dy-dy-relrelated dated
of all subjeof all sub
dy.  Subjecty.  Subjec
uments.uments.
of the of the InveInve
ve queries aqueries 
ital charts, al charts
st ensure tst ensure 
rmation amation 
obtain inforbtain info
lated proceated proc
that informhat inform
formed conformed con
the date.  The date.  T
and by [CONTACT_72647], m, must be ust bemm
n additn addit ioion, n,
informnform eded
memendnd
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 57 CC-486-NPC-001 Final: [ADDRESS_78749]'s right to protecti on against invasion of privacy and to be in 
compliance with ICH and other local regulations (whichever is most stringent). Celgene requires 
the Investigator to permit Celgene's representatives and, when necessary, representatives from 
regulatory authorities, to review and/or copy an y medical records relevant to the study in 
accordance with local laws.
Should direct access to medical records require a waiver or authorization separate from the 
subjectâ€™s signed informed consent document, it is the responsibility of the Investigator to obtain 
such permission in writing from the appropriate individual.
14.5. Protocol Amendments
Any amendment to this protocol must be approved by [CONTACT_27730]/Medical Monitor.  Amendments will be submitted to the IRB/EC for written approval.  Written approval must be obtained before implementation of the amended version occurs.  The 
written signed approval from the IRB/EC should specifically reference the Investigator n ame, 
protocol number, study title and amendment number(s) that is applicable. Amendments that are 
administrative in nature do not require IRB/IEC approval but will be submitted to the IRB/IEC 
for information purposes.
14.6. Institutional Review Board/Independent Ethics Committee Review 
and Approval
Before the start of the study, the study protocol , informed consent docu ment, and any other 
appropriate documents will be submitted to the I RB/EC with a cover letter or a form listing the 
documents submitted, their dates of issue, and the site (or region or area of jurisdiction, as 
applicable) for which approval is sought. If applicable, the documents will also be submitted to 
the authorities in accordance with local legal requirements.
IP can only be supplied to an Investigator by [CONTACT_72648] a nd legal requirements for starting the study has been received by 
[CONTACT_72649]. This  documentation must also include a list of the 
members of the IRB/EC and their occupation and qualifications. If the IRB/EC will not disclose the names, occupations and qualifications of th e committee members, it should be asked to issue 
a statement confirming that the composition of the committee is in accordance with GCP. For example, the IRB General Assurance Number may be accepted as a substitute for this list. Formal approval by [CONTACT_1201]/EC should mention the protocol title, number, amendment number 
(if applicable), study site (or region or area of jurisdiction, as applicable), and any other 
documents reviewed. It must mention the date on which the decision was made and must be officially signed by a commi ttee member. Before the first subject is enrolled in the study, all 
ethical and legal requirements must be met.
The IRB/EC and, if applicable, the authorities, must be informed of all subsequent protocol 
amendments in accordance with local legal requirements. Amendments must be evaluated to 
determine whether formal approval must be sought and whether the informed consent document 
should also be revised.&(/*(1([ZIP_CODE],(7$5<,1)250$7,21ain n
arch arch 
or written aor written a
versioversio n ocno c
the InvestiInves
able. ble. AmenAme
[CONTACT_72656]
e IRB/EC wIRB/EC w
nd the site nd the site 
. If applicab If appli
alalllllegalegal reqll
ststigatorigator byb
nd legal reqnd legal re
presentativpresentat
and their oand their
ns and qualins and qu
ming that thming that th
B General B General 
oval by [CONTACT_72650]), studyle), study
nts reviewnts review
cially signecially signe
hihical and lcal and 
The IRBThe IR
en
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 58 CC-486-NPC-001 Final: [ADDRESS_78750] of all co mmunication with the IRB /EC and, if applicable, 
between a Coordinating Investigator [INVESTIGATOR_72616]/EC. This statement also applies to any 
communication between the Investigator (or Coordinating Investigator, if applicable) and 
regulatory authorities.
Any advertisements used to recruit subjects for the study must be reviewed by [CONTACT_27734]/EC prior to use.
14.7. Ongoing Information for Institutional Review Board / Ethics 
Committee
If required by [CONTACT_27735]/EC, the Investigator must submit to the IRB/EC:
!Information on serious or unexpected adverse events as soon as possible;
!Periodic reports on the progress of the study;
!Deviations from the protocol or anything th at may involve added risk to subjects.
14.8. Closure of the Study
Celgene reserves the right to terminate this study at any time for reasonable medical or 
administrative reasons. Any premature discontinuation will be appropriately documented according to local requirements (eg, IRB/EC, regulatory authorities, etc...).
In addition, the Investigator or Celgene has the right to discontinue a single site at any time 
during the study for medical or administrative reasons such as:
!Unsatisfactory enrollment;
!GCP noncompliance;
!Inaccurate or incomplete data collection;
!Falsification of records;
Failure to adhere to the study protocol.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21e;e;
ed risk to sued risk to su
reasonableasonable
e appropriae appropr
uthorihorititiiiies, ees,
o disconto discont inuinu
ns such asns such a
ta collecta collect ioi
;;
protocolprotocol .
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 59 CC-486-NPC-001 Final: 11 July 201415. DATA HANDLING AND RECORDKEEPI[INVESTIGATOR_1645]
15.1. Data/Documents
The Investigator must ensure that the records and documents pertaining to the conduct of the 
study and the distribution of the investigat ional product are complete, accurate, filed and 
retained.  Examples of source documents include: hospi[INVESTIGATOR_1097]; clinic and office charts; laboratory notes; memoranda; subjectâ€™s diaries or evaluation checklists; dispensing records; 
recorded data from automated instruments; copi[INVESTIGATOR_27602]; microfiche; x-ray film and re ports; and records kept at the pharmacy, and 
the laboratories, as well as copi[INVESTIGATOR_27603]-ROM.
15.2. Data Management
Data will be collected via CRF and entered into the clinical database per Celgene standard operating procedures (SOPs). This data will be electronically verified through use of programmed edit checks specified by [CONTACT_6098].  Discrepancies in the data will be brought 
to the attention of the clinical team, and investigational site personnel, if necessary.  Resolutions 
to these issues will be reflected in the database.  An audit trail within the system will track all changes made to the data.
15.3. Record Retention
Essential documents must be retained by [CONTACT_72651] a minimum of [ADDRESS_78751] retain these documents for the time period described above or according to local laws or requirements, whichever is longer.  Essential documents include, but are not limited to, the following:
!Signed informed consent documents for all subjects;
!Subject identification code list, screening log (if applicable), and enrollment log;
!Record of all communications between the Investigator and the IRB/EC;
!Composition of the IRB/EC;
!Record of all communications between the Investigator, Celgene, and their aut horized 
representative(s);
!List of Sub-Investigators and other appropriately qualified persons to whom the Investigator has delegated significant study-related duties, together with their roles in 
the study, curriculum vitae, and their signatures;
!Copi[INVESTIGATOR_3110] (if paper) and of documentation of corrections for all subjects;
!IP accountability records;
!Record of any body fluids or tissue samples retained;&(/*(1([ZIP_CODE],(7$5<,1)250$7,21on as n as 
macyacy, and , and
elgene elgene stanstan
hrough use ugh us
es in the das in the d
nnel, if necenel, if nec
witithin the shin 
stigatorstigator fofor
region and egion and
CH region,CH region,
pment of thpment of th
ed above ord above o
mments inclents inc
nsent documnsent docum
catatioion coden cod
ll coll commummu nn
osisititiiion ofon of  ththff
cord of all ord of all
represenrepresen tattatnn
!!List ofList of
InvInv
t
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 60 CC-486-NPC-001 Final: 11 July 2014!All other source documents (subject records, hospi[INVESTIGATOR_1097], laboratory records, 
etc.);
!All other documents as listed in Section 8 of the ICH consolidated guideline on GCP 
(Essential Documents for the Conduct of a Clinical Trial).
The Investigator must notify Celgene if he/she wishes to assign the essential documents to 
someone else, remove them to another location or is unable to retain them for a specified period.  The Investigator must obtain approval in writi ng from Celgene prior to destruction of any 
records. If the Investigator is unable to meet this obligation, the Investigator must ask Celgene 
for permission to make alternative arrangements. Details of these arrangements should be documented.
All study documents should be made availabl e if required by [CONTACT_27737]. 
Investigator/Institution should take measures to prevent accidental or premature destruction of 
these documents.e 
ities. ties.
destrdestr uctionuction
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 61 CC-486-NPC-001 Final: [ADDRESS_78752] 
operating procedures.
16.1. Study Monitoring and Source Data Verification
Celgene ensures that appropriate monitoring procedures are performed before, during and after 
the study.  All aspects of the study are review ed with the Investigator and the staff at a study 
initiation visit and/or at an Investigator meeting.  Prior to enrolling subjects into the study, a 
Celgene representative will review the protoc ol, CRFs, procedures for obtaining informed 
consent, record keepi[INVESTIGATOR_007], and reporting of AEs/ SAEs with the Investigator.  Monitoring will 
include on-site visits with the Investigator and his/her staff as well as any appropriate 
communications by [CONTACT_2319], email, fax, or telephone.  During monitoring visits, the facilities, investigational product storage area, CRFs, subjectâ€™s source documents, and all other study 
documentation will be inspected/reviewed by [CONTACT_27738].
Accuracy will be checked by [CONTACT_12939] a direct comparison of 
the entries made onto the CRFs against the appropriate source documentation.  Any resulting 
discrepancies will be reviewed with the Investigator and/or his/her staff.  Any necessary corrections will be made directly to the CRFs or via queries by [CONTACT_11219]/or his/her 
staff. Monitoring procedures require that informed consents, adherence to inclusion/exclusion 
criteria and documentation of SAEs and their proper recording be verified.  Additional 
monitoring activities may be outlined in a study-specific monitoring plan.
16.2. Audits and Inspections
In addition to the routine monitoring procedure s, a Good Clinical Practice Quality Assurance 
unit exists within Celgene.  Representatives of this unit will conduct audits of clinical research 
activities in accordance with Celgene SOPs to evaluate compliance with Good Clinical Pract ice 
guidelines and regulations.
The Investigator is required to permit direct access to the facilities where the study took place, 
source documents, CRFs and app licable s upporting records  of study subject participation for 
audits and inspections by [CONTACT_1744]/IECs, regulatory au thorities (eg, FDA, EMA, Health Canada) and 
company authorized representatives.  The Investig ator should make every effort to be available 
for the audits and/or inspections.  If the Invest igator is contact[CONTACT_72652], he/she should contact [CONTACT_27740].
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21fter ter 
udy dy 
udydy, a, a
formed formed 
itoring willitoring wil
ropriate ropriate 
ts, the facils, the facil
 and all othnd all 
tive in accoive in acc
oon that in that s a
rce documece docum
d/or his/her d/or his/he
queriequer s bys bty
d consents, d consents, 
roper recoroper reco
udyudy--specifispecifi
s
ng procedung procedu
presentativeresentative
Celgene SCelgene
s.
quired to pquired to
 CRFs andCRFs and
ectectioions by [CONTACT_72653] I
thorized repthorized rep
ditstsiand/or nd/or 
ing an inspeng an inspe
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 62 CC-486-NPC-001 Final: [ADDRESS_78753] authorship 
will be based on several considerations, including, but not limited to study participation, 
contribution to the protocol development, and analysis and input into the manuscript, related 
abstracts, and presentations in a study.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 63 CC-486-NPC-001 Final: 11 July 201418. REFERENCES
Ahmad A, Stefani S. Distant metastases of nasopharyngeal carcino ma: a study of 256 male 
patients. J Surg Oncol 1986;33:194-197.
Al-Sarraf M. Head and neck cancer: chemotherapy concepts. Semin Oncol 1988;15:70-85.
American Cancer Society: Nasopharyngeal Cancer. September 23, 2013. Available at : 
http://www.cancer.org/cancer/nasopharyngealcancer/detailedguide/nasopharyngeal-cancer-what-
is-nasopharyngeal-cancer. Accessed February 26, 2014.
Baujat B, Audry H, Bourhis J, et al. Chemoth erapy in locally advanced nasopharyngeal 
carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. 
Int J Radiat Oncol Biol Phys 2006;64:47-56.
Bensouda Y, Kaikani W, Ahbeddou N, et al. Treatment for metastatic nasopharyngeal 
carcinoma. Eur Ann Otorhinolaryngol Head Neck Dis 2011;128:79-85.
Chan AT, Gregoire V, Lefebvre JL, et al. Nasopharyngeal cancer: EHNS-ESMO-ESTRO 
Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;([ADDRESS_78754] 5):v187-189.
Chan AT, Tao Q, Robertson KD, et  al. Azacitidine induces demet hylation of the Epstein-Barr 
virus genome in tumors. J Clin Oncol 2004;22:1373-1381.
Chua D, Wei WI, Sham JS, et al. Capecitabin e monotherapy for recurrent and metastatic 
nasopharyngeal cancer. Jpn J Clin Oncol 2008;38:244-249.
Chua DT, Sham JS, Au GK. A phase II study of capecitabine in patients with recurrent and 
metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy. Oral Oncol 
2003;39:361-366.
Ciuleanu E, Irimie A, Ciuleanu TE, et al. Capecitabine as salvage treatment in relapsed 
nasopharyngeal carcinoma: a phase II study. J BUON 2008;13:37-42.
Dugan M, Choy D, Ngai A, et al. Multicenter phase  II trial of mitoxantrone in patients with 
advanced nasopharyngeal carcinoma in Southeast Asia: an Asian-Oceanian Clinical Oncology 
Association Group Study. J Clin Oncol 1993;11:70-76.
Foo KF, Tan EH, Leong SS, et al. Gemcitabine in metastatic nasopharyngeal carcinoma of the 
undifferentiated type. Ann Oncol 2002;13:150-156.Garcia-Manero G, Gore SD, Cogle C, et al.  Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic 
leukemia, and acute myeloid leukemia. J Clin Oncol 2011;29:2521-2527.
Jacobs C, Lyman G, Velez-Garcia E, et al. A phase III randomized study comparing cisplatin 
and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of 
the head and neck. J Clin Oncol 1992;10:257-263.
Kenney SC, Mertz JE. Regulation of the latent-lytic switch in Epstein-Barr virus. Semin Cancer 
Biol 2014;26:60-68. Available at: http://dx.doi.org/10.1016/j.semcancer.2014.01.002.&(/*(1([ZIP_CODE],(7$5<,1)250$7,21atat--
753 patient753 patien
haryngeal haryngeal
HNSNS--ESMOESMO
. Ann Onco. Ann On
demethylatdemethylat
1..
otherapytherapy fyyorf
:244244-249.-249.
ofof capeci capeciff tataiii
eated witated wit hh
et al. et al. CapeCap
ase II studyase II study
et al. et al. MulMtiil
carcinocarcino m
dydy. J Clin O. J Clin 
Leong SS, Leong SS, 
d tyd type.pe.y AnnAnn
yyofofy oral oraff  az azll
and acute nd acute 
s C, Lymans C, Lyma
d fluorourafluoroura
thhe head ane head an
enneenne
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 64 CC-486-NPC-001 Final: 11 July 2014Koutcher L, Lee N, Zelefsky M, et al. Reirradiation of locally recurrent nasopharynx cancer with 
external beam radiotherapy with or without brac hytherapy. Int J. Radiat Oncol Biol Phys 
2010;76:130-137.
Lo KW, Chung GTY, To KF, et al. Acquired genetic and epi[INVESTIGATOR_72617]. In: Busson P, ed. Nasopharyngeal Carcinoma. [LOCATION_001], 
NY:Springer [LOCATION_001];2013:61-81.
Ma BB, Chan AT. Recent perspectives in the role of chemotherapy in the management of 
advanced nasopharyngeal carcinoma. Cancer 2005;103:22-31.
Mendenhall WM, Werning JW, Pfister DG. Treatment of head and neck cancer. In: DeVita VT 
Jr, Lawrence TS, Rosenberg SA: Cancer: Principles and Practice of Oncology. 9thed. 
Philadelphia, PA. Lippi[INVESTIGATOR_4431] & Wilkins;2011:729-780.
Miranda MB, Jones PA. DNA methylation: the nut s and bolts of repression. J Cell Physiol
2007;213:384-390.
Ngeow J, Lim WT, Leong SS, et al. Docetaxel is effective in heavily pretreated patients with 
disseminated nasopharyngeal carcinoma. Ann Oncol 2011;22:718-722.
Okada T, Nakamura M, Nishikawa J, et al. Identification of genes specifically methylated in 
Epstein-Barr virus-associated gastric carcinomas. Cancer Sci 2013;104:1309-1314.
Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern 
Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655.
Ong YK, Heng DM, Chung B, et al. Design of a prognostic index score for metastatic 
nasopharyngeal carcinoma. Eur J Cancer 2003;39:1535-1541.
Paulson EJ, Speck SH. Differential methylation of Epstein-Barr virus latency promoters 
facilitates viral persistence in healthy seropositive individuals.  J Virol 1999;73:9959-9968.
Robertson KD, Ambinder RF. Methylation of the Epstein-Barr virus genome in normal 
lymphocytes.  Blood 1997;90:4480-4484.
Salamon D, Takacs M, Ujvari D, et al. Protein -DNA binding and CpG methylation at nucleotide 
resolution of latency-associated promoters Qp, Cp, and LMP1p of Epstein-Barr virus. J Virol 
2001;75:2584-2596.
Sham JS, Cheung YK, Choy D, et al. Computed tomography evaluation of neck node metastases 
from nasopharyngeal carcin oma. Int J Radiat Oncol Biol Phys 1993;26:787-792.
Sham JS, Choy D, Wei WI. Nas opharyngeal carcinoma; orderly neck node spread. Int J Radiat 
Oncol Biol Phys 1990;19:929-933.
Shiu WCT, Tsao SY. Efficacy of 4'-epi[INVESTIGATOR_72618]. Clin 
Trials J 1989;26:419.
Simon R. Optimal two-Stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-
10.
Tierney R, Kirby H, Nagra J, et al. The Epstein-Barr virus promoter initiating B- cell 
transformation is activated by [CONTACT_72654] a nd the B-cell-specific activator protein BSAP/Pax5.  
J Virol 2000;74:[ZIP_CODE]-[ZIP_CODE].&(/*(1([ZIP_CODE],(7$5<,1)250$7,21ta VT a VT 
Cell Physioell Phys l
etreated patreated 
2.2.
s specificalspecifical
2013;104:1013;104
sponse critsponse cri
:649:649-655.655.
ognostic inognostic in
9:[ZIP_CODE]:[ADDRESS_78755], Tsao
als J 1989;ls J 1989;
SiSimomn R.n R.
00
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 65 CC-486-NPC-001 Final: 11 July 2014Thompson LD. Update on nasopharyngeal carcinoma. Head Neck Pathol 2007;1:81-86.
Vikram B, Strong EW, Shah JP, et al. Intraoperative radiotherapy in patients with recurrent head 
and neck cancer. Am J Surg 1985;150:485-487.
Zhang L, Zhang Y, Huang PY, et al. Phase II clinical study of gemcitabine in the treatment of
patients with advanced nasopharyngeal carcinoma after the failure of platinum-based 
chemotherapy. Cancer Chemother Pharmacol 2008;61:33-38.
Zhang X, Li W, Li H, et al. Genomic me thylation prof iling combined with gene expression 
microarray reveals the aberrant methylation mechanism involved in nasopharyngeal carcinoma 
taxol resistance.  Anticancer Drugs 2012b;23:856-864.Zhang Z, Chen F, Kuang H, et al. Epi[INVESTIGATOR_72619]. In: Chen SS, ed. 
Carcinogenesis, Diagnosis, and Molecular Targeted Treatment for Nasopharyngeal Carcinoma. 
Intech Open; ISBN:978-953-307-867-0;2012a:1-27.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21ma ma
n SS, ed. n SS, ed. 
l CarcinoCarcino mm
('06'RF1XPEHUCC-486 (Oral Azacitidine)
CC-486-NPC-001 Celgene Corporation
Confidential and Propri etary 66 CC-486-NPC-001 Final: 11 July 201419. APPENDICES
Appendix A. Eastern Cooperative Oncology Group (ECOG) Performance 
Status
Table 5: Eastern Cooperative Oncology Group (ECOG) Performance Status
Grade ECOG
0 Fully active, able to carry on all pre-disease performance without restriction.
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a 
light or sedentary nature, eg, light house work, office work.
2 Ambulatory and capable of all self-care but unable to carry out any work activities. Up and 
about more than 50% of waking hours.
3 Capable of only limited self-care, confined to bed or chair more than 50% of waking hours.
4 Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair.
5D e a d .
Source: Oken, 1982 .
&(/*(1([ZIP_CODE],(7$5<,1)250$7,2177$7$7$7$7 work of a ork of a 0$
activities. Uactivities5
han 50% of wan 50%)2onfined to bnfined to 1),1
5<
('06'RF1XPEHU
Celgene Signing Page
This is a representation of an electronic record that was signed electronically in Livelink.
This page is the manifestation of the electronic signature(s) used in compliance with
the organizations electronic signature [CONTACT_13695].
8VHU1DPH 
7LWOH 
'DWH)ULGD\-XO\30(DVWHUQ'D\OLJKW7LPH0HDQLQJ$SSURYHGQRFKDQJHVQHFHVVDU\                                                
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21   